Cloud DX Annual Report 2018

← All annual reports

FY2018 Annual Report · Cloud DX

Loading PDF…

Annual Report
2 0 1 8

CARDIEX LIMITED
(FORMERLY ATCOR MEDICAL HOLDINGS LIMITED)
ABN 81 113 252 234
AND CONTROLLED ENTITIES

CONTENTS

Letter from the Chairman

Corporate Directory

Letter from the Chief Executive Officer

Operational Update

Directors’ Report

Remuneration Report

Auditor’s Independence Declaration

Consolidated Statement of Profit or Loss and Other Comprehensive Income

Consolidated Statement of Financial Position

Consolidated Statement of Changes In Equity

Consolidated Statement of Cash Flows

Notes to the Consolidated Financial Statements

Directors’ Declaration

Independent Auditor’s Report

CARDIEX - ANNUAL REPORT 2018LETTER FROM THE
CHAIRMAN

Dear Shareholder,

It is my pleasure as the former Chairman of AtCor Medical Holdings Limited to write to you now my first
Chairman’s letter of ‘Cardiex Limited’, our newly rebranded Company.

As outlined in the CEO’s report on pages 7 to 8, 2017/18 has been a challenging but exciting year during which
AtCor has changed its operating model and cost structure to reduce its reliance on pharma revenues, which can
fluctuate greatly year-to-year, while positioning the business for future growth and profitability in new market
segments.

Renewal at both the board and senior management level continued during 2018, in line with the changes
announced last year: principally being the retirement of Professor Michael O’Rourke, co-founder of the company
and inventor of SphygmoCor technology, and Dr David Brookes, a longtime Non-Executive Director. Long-serving
Managing Director, Duncan Ross, also transitioning out of his executive role during the year.

Since that time the Company appointed a new CEO, Mr Craig Cooper, who has brought a new energy and focus to
the Company and has continued to look for new growth opportunities and ways to optimise our cost structure.

Mr Niall Cairns was also welcomed to the Board in late 2017 and together with Craig has worked to provide a
new range of expertise and contacts that have assisted in the development and execution of a revised strategic
plan.

In preparation of these changes and in putting in place the building blocks for such growth the company held a
transformational Extraordinary General Meeting of shareholders in May 2018.

At this meeting the company received overwhelming shareholder support for some substantially accretive
shareholder milestones:

• The rebranding and change of name of the listed parent entity from AtCor Medical Holdings Limited to

CardieX Limited and a revised ASX ticker code to ASX:CDX;

• The completion of a tranched funding facility of $5,000,000 to position the Company to be funded for
growth opportunities. It should be noted that the CEO Mr Craig Cooper and Director Mr Niall Cairns
personally supported this fund raising by jointly contributing $1,500,000 in funding (30% of the total
$5,000,000 raised);

CARDIEX - ANNUAL REPORT 2018• Announcement of and completion of the first tranche investment into Blumio, Inc, a Silicon Valley

based developer of non-invasive radar-based sensors designed to measure blood pressure and other
cardiovascular diagnostics. Under this transaction CardieX committed to invest up to USD$600,000 in
Blumio, Inc for a 7.5% shareholding.

The completion of these transactions and funding capabilities also led to the announcement of key
restructures made effective prior to 30 June 2018 namely:

• Promotion of long serving employee Mr Doug Kurschinski. Doug has been promoted to Executive Vice

President and Head of Global Sales of CardieX’s AtCor Medical division in place of the Company’s former
CEO Mr Duncan Ross. This also consolidated the role of the Australian head of sales leading to further
cost optimisations and synergies in the sales team;

• Appointment of Jarrod White as CFO and Company Secretary on an outsourced basis to provide local

flexibility and scalability to the global business;

• Creation of a new role in the Director of Corporate Development and the appointment of Mr ZiHan Lin
to that Role. Mr Lin was formerly the Director of North Asia for Masimo, Inc, the US$5B market cap
(NASDAQ:MASI) listed medical device company where he focused on the Chinese and Asian strategy for
Masimo’s portfolio of devices.

• Appointment of Ms Rhona Welch as a member of the Company’s Advisory Board to lend support to the
Board and Management. Ms Welch, who will be working closely with the Company’s executive team in
the development of new opportunities, is a 20-year veteran of the US healthcare industry and was a
former Director of Health Policy Reimbursement at Johnson & Johnson.

The mobilization of this Executive Team means that CardieX is poised for transformational growth. A key
focus is to identify further opportunities to expand the use and value of its core intellectual property in the
areas of cardiovascular and hypertension measurement and diagnostics as well as pursue other technology
opportunities in large scale population health disorders.

The Board continues to believe that the SphygmoCor technology has tremendous upside in both its current
market segments and in new markets and applications. Investment will continue in developing new IP and
evolving the current product suite.

The company appreciates the continued commitment which shareholders have shown throughout the year in
raising over $5,000,000 of equity funding through various capital raising initiatives.

These funds will be used to pursue our new strategy and vision to become a leading global health technology
company.

We look forward to keeping you apprised of progress, and sincerely thank you for your continued support.

Donal O’Dwyer
Sydney, Australia 31 October 2018

CARDIEX - ANNUAL REPORT 2018

CORPORATE DIRECTORY

Directors

Mr. Donal O’Dwyer (Chairman)

Share Registry

Link Market Services

Mr. Niall Cairns, appointed 20 December 2017

Level 12, 680 George street

Mr. King Nelson

Sydney NSW 2000

Mr. Craig Cooper, appointed 01 December 2017

Telephone: (02) 8280 6000

Dr. David Brookes, resigned 03 April 2018

Website: www.Linkmarketservices.com

Mr. Duncan Ross, resigned 20 December 2017

Auditors

Dr. Michael O’Rourke, resigned 30 November 2017

Company Secretary

BDO East Coast Partnership

Level 11, 1 Margaret street

Mr. Jarrod White, appointed 05 March 2018

Sydney NSW 2000

Mr. Peter Manley, resigned 05 March 2018

Telephone: (02) 9251 4100

Chief Financial Officer

Mr. Jarrod White, appointed 05 March 2018

Facsimile: (02) 9240 9821

Website: www.BDO.com.au

Mr. Peter Manley, resigned 05 March 2018

Corporate Accountant

Registered Office and Principal Place of Business

Suite 11, 1059 – 1063 Victoria Road
West Ryde NSW 2114

Traverse Accountants

Suite 305, Level 3

35 Lime Street

Sydney NSW 2000

Telephone: (02) 9874 8761

Email: info@cardiex.com

Website: www.CardieX.com

Website: www.Traverseaccountants.com.au

Stock Exchange Listing

CardieX Limited’s shares are listed on the Australian
Securities Exchange (ASX code: CDX).

CARDIEX - ANNUAL REPORT 2018

LETTER FROM THE
CHIEF EXECUTIVE
OFFICER

Dear Fellow Shareholders,

I am delighted to present my first Annual Report as the new CEO of CardieX - reflecting on a year where we
embarked on a major restructuring program and laid the foundation to position our company as the world
leader in hypertension and cardiovascular health management.

This past year has been a year of change with a new corporate name and brand - “CardieX” - (formerly “AtCor
Medical”), a restructured executive team, and a new strategic vision.

Our fundamental market opportunity however remains the same as we continue to develop health solutions
for large-scale population health disorders with a current focus on patients with hypertension, cardiovascular
disease (CVD), and related conditions – such as stroke, diabetes, and Alzheimer’s disease. With over half the
USA adult population now considered hypertensive and at risk for CVD, CardieX is positioning itself as the gold
standard for diagnosis, treatment and management of those patient populations with its core Sphygmocor®
technology and (FDA approved) XCEL line of medical devices.

Our vision as we move forward is to create an ecosystem and portfolio of assets, medical & consumer
devices, and digital health platforms that provide both patients and health practitioners with the key products
they need to better manage patient outcomes. At the core of our global CVD strategy is our Sphygmocor®
technology, as well as our intellectual property (IP) and patents, which all-together gives CardieX a significant
competitive advantage as we leverage our technology and medical devices into new markets, products, and
next generation health services.

One example of this is our recent financial and strategic partnership with Blumio, Inc, a Silicon Valley based
developer of non-invasive radar-based sensors designed to measure blood pressure and other cardiovascular
diagnostics. Earlier in the year CardieX committed to invest up to US$600,000 in Blumio, Inc for a 7.5%
Shareholding.

CARDIEX - ANNUAL REPORT 2018L E T T E R F R O M T H E C H I E F E X E C U T I V E O F F I C E R

As part of this investment, Blumio, Inc and CardieX also signed a “Collaboration and Development Agreement”
to co-develop wearable sensor technology to measure blood pressure (BP) which combines our Sphygmocor®
IP with Blumio’s BP sensor.

Commensurate with our development efforts with Blumio, we are also continuing to pursue licensing
opportunities and other partnerships to incorporate our Sphygmocor® technology and IP with other global
leaders in consumer health wearables and devices. Further details are provided below in the “Operational
Update”.

Another key shift is our focus on two new growth markets for sales of our products – China, as well as general
medical and naturopathic health professionals and executive health clinics.

To date our sales focus has been in the USA where the majority of our global revenues are historically derived.
Commensurate with the growth in CVD and other related health disorders in China we are expanding our
(existing) distribution and sales network in that country for our existing “Chinese FDA” approved (CFDA) XCEL
Sphygmocor® device - while also exploring the opportunities for other strategic partnerships in that region.

Similarly, we are expanding our sales focus in the USA beyond our traditional specialist markets (Cardiologists
and Nephrologists) to a wider medical health professional market increasing our potential addressable sales
market size by over 30x. As part of this new market focus we will also be launching new product derivatives
based on our existing XCEL Sphygmocor® that directly targets these non-specialist health markets.

And finally, we are progressing with a number of digital and mobile health initiatives that provide patients with
better tools to manage their health and wellness. A number of these efforts are fuelled by recent changes in
US CPT codes that provide for time-based reimbursement to medical professionals using digital health tools
to remotely monitor patients.

In closing, I would like to take this opportunity to thank my fellow board members and the executive
management and staff of CardieX. I also want to thank all shareholders for their ongoing support as we
continue to position the Company for growth and new market opportunities.

I believe the success of our recent heavily oversubscribed share placement and rights issue shows strong
validation for our new strategy and direction. I expect the year ahead to continue to be a transformative and
exciting one as we execute against our plan and new strategic direction.

Craig Cooper
CEO & Managing Director
CardieX Limited

CARDIEX - ANNUAL REPORT 2018OPERATIONAL UPDATE

Overview of Corporate Strategy and Mission

CardieX is a global health technology company focused on developing products and solutions for large-
scale population health disorders. Our “AtCor Medical” division develops and markets products for the early
detection of target organ damage and the management of hypertension, cardiovascular disease (CVD), and
related health disorders - the #1 killer of humans globally. As discussed below (see: “Key Highlights”), this past
year has been one of significant change with the Company’s operational, product, and sales focus over the last
12 months being directed towards:

• Aligning the Company with world-class partners in our mission to become the market leader in CVD and

hypertension related medical devices.

• Positioning the Company to take advantage of new opportunities in digital health and new products and

services through the recruitment of key new executive talent.

• Rebranding the Company’s corporate name, image, and messaging to reflect our focus on solutions for

large scale population health disorders.

• Restructuring our product offerings to take advantage of new target market segments outside of our

traditional specialist practitioner markets.

• Restructuring our global executive team and Board of Directors to maximize our in-house corporate

intelligence around new market opportunities and technologies.

•

Importantly - reducing the operating cash loss attributable to our existing “AtCor” business unit while
reallocating cash reserves to new growth and business initiatives.

• Generally re-positioning the Company for growth in new geographies and health technology markets.

Key Corporate, Strategic, and Sales Highlights

The last 12 months have been a period of significant change and restructuring within the Company as CardieX
positions itself for growth in new market segments and geographies.

Key Corporate Highlights Include:

• Significant change in strategy and corporate vision implemented for the Company.

• Change of name and corporate branding to CardieX (ASX:CDX).

• Appointment of new CEO & Managing Director – Craig Cooper.

• Major restructuring of global executive and sales teams and Board of Directors.

• Successful heavily oversubscribed new capital raising to support new initiatives and growth strategy.

• Signed Convertible Note Purchase Agreement and “Development & Collaboration Agreement” with
Blumio, Inc aligning CardieX with a strong Silicon Valley technology partner for our wearable device
strategy.

CARDIEX - ANNUAL REPORT 2018O P E R A T I O N A L U P D A T E

• First instalment of investment capital in Blumio, Inc made in Q2, 2018. The Company is committed to pay

the second instalment of US$450,000 in Q4 2018.

• Completed successful CardieX/Blumio, Inc blood pressure sensor trial with Macquarie University.

• Zihan Lin appointed as “Director of Corporate Development” to focus on Chinese sales strategy,

wearables, and digital health initiatives.

• New Chief Financial Officer & Company Secretary – Jarrod White.

• Ex-Johnson & Johnson executive, Rhonda Welch, appointed to assist in reimbursement and strategic

initiatives in new health sectors.

• Appointment of a new communications and investor relations team (NWR Communications).

• Appointment of a new marketing agency to oversee new website development, corporate messaging and

digital communications strategy.

Key Sales Highlights Include:

• Global sales force restructured. Duncan Ross & Mark Harding exited.

• Doug Kurschinski appointed new “EVP & Head of Global Sales”.

• Global distribution partnerships restructured in terms of management and country focus - all global

distribution now managed from USA.

• Expansion of our sales and market focus in the USA to include a broader range of health & wellness

professionals combined with a targeted “direct to practitioner” marketing strategy.

• Renewed market focus on Asia with enhanced distribution and sales strategy specifically in China.

• A signed agreement with New York University (NYU) - representing a major entry point into the New York

health systems market.

• Three new contracts signed to supply Sphygmocor® systems and clinical trial support services to global

pharmaceutical companies.

• A multi-practice supply agreement signed with executive health provider - Physioage Systems.

Further details on these select highlights and operational updates are provided below.

CARDIEX - ANNUAL REPORT 2018Atcor Medical Division Sales Overview

In clinical practice and clinical trials, Sphygmocor® XCEL is the industry standard for non-invasive central
arterial waveform assessment and management. The Company’s Sphygmocor® XCEL device provides
measures of the central aortic blood pressure (the blood pressure at the heart) and pulse wave velocity, as well
as assessment of arterial stiffness via waveform analysis.

The practical application of the Company’s Sphygmocor® XCEL device is through the measurement of blood
pressure (BP) dynamics at the organ level (e.g. heart/kidneys), compared to traditional measurements of BP
via a standard brachial cuff. Measurement of BP and other blood flow dynamics at the organ with XCEL allows
a more accurate diagnosis and reading of the state of a patient’s cardiovascular health, thereby providing
better, and more targeted treatment options.

During the past year the Company signed three new contracts and seven amendments, or extensions for
existing contracted clinical trials, all with major international pharmaceutical companies. In these trials, the
Company supplies Sphygmocor® systems and clinical trial support and data management services. The
combined value of these agreements was AU$1.55 million.

During July, the Company signed a two-year supply agreement with New York University (NYU). Under the
agreement, the Company will provide Sphygmocor® systems to NYU owned and affiliated locations and
practices.

During September 2017, Viking Yacht company, a leader in semi-custom fiberglass yacht production, added
the Company’s Sphygmocor® XCEL to its employee wellness program. With Sphygmocor®, Viking Yacht
company employees receive access to leading technology for central blood pressure and arterial stiffness
measurements, which help to better inform their blood pressure management. Corporate wellness is an
emerging part of the clinical market and an important growth segment for the Company moving forward.

In January, the Company entered into a multi-year supply agreement with Physioage Systems, a leader in the
use of biomarkers of aging and personalised health analytics. The two-year agreement will streamline the
integration of Sphygmocor® into the Physioage program.

Sphygmocor® is now used in all 20 hospitals on the U.S. News 2018-2019 “Honor Roll”. Each year, U.S. News
& World Report releases its hospital honor roll of the top 20 hospitals in the USA. This last year also saw
the Company highlighted in major journals and research reports including: Journal of the American Heart
Association, Journal of the American Society of Hypertension, Journal of Alzheimer’s Disease, and others.

Blumio, Inc Financial & Strategic Partnership

As part of the Company’s focus on new technology markets the Company is aggressively focused on
leveraging its core Sphygmocor® technology into new products, wearables, and devices. The global
opportunity in wearable blood pressure and cardiovascular management sensors is over $US2B and CardieX
has a portfolio of specific patents and intellectual property (IP) that has significant commercial value in this
market segment. In particular, our IP and experience in obtaining central blood pressure (CBP) is critical to
proper diagnosis and management of hypertension and CVD. The development of a sensor-based wearable
combining central blood pressure (CBP) and standard blood pressure (BP) is considered to be a game-changer

CARDIEX - ANNUAL REPORT 2018for continuous blood pressure monitoring in this multi-billion dollar market segment.

During March 2018, the Company took an initial step to position itself for growth in these new technology
markets and signed a “Development and Collaboration Agreement” with Blumio, Inc, (Blumio), a California,
Silicon Valley based developer of sensor and wearable technology for blood pressure detection and other
cardiovascular diagnostics.

The agreement provides the framework for the development and integration of the Company’s IP, patents,
and CBP technology into Blumio’s sensors and will see the parties collaborate and develop new technology
applications for the sensor-based detection of cardiovascular disease.

An agreement was also made for CardieX to invest up to US$600,000 (subject to certain capital raise, due
diligence, and other conditions) in Blumio. This investment allows CardieX to obtain up to a 7.5% equity
shareholding in Blumio.

During May 2018, CardieX announced that it would commence a preliminary trial of the feasibility of
integrating its Sphygmocor® technology with Blumio’s sensor. The preliminary trial would be undertaken at
the Faculty of Medicine and Health Sciences at Macquarie University, Sydney.

As part of the planned 15 patient 8-week trial, CardieX would independently assess the feasibility of obtaining
cardiovascular BP-related data utilising the Blumio, Inc wearable sensor and analysing it via CardieX’s
Sphygmocor® technology.

This was a multi-phase program: the first phase of the assessment was to collect sensor data from at least
15 human subjects covering different age groups, different genders and a range of BP characteristics. This
first phase aimed to assist in determining the amount of cardiovascular-related information available from the
sensor as well as define the next steps towards commercialisation of a wearable sensor-based product.

The results from this first phase trial were released in July 2018 and provided positive evidence that with the
further application of CardieX’s machine learning algorithms and IP, central blood pressure (CBP) parameters
can be successfully derived from the Blumio, Inc sensor towards a positive commercial outcome.

Corporate Restructure And Name Change

At the start of the year CardieX announced the first phase of a major company restructure to maximise
profitability, reduce costs, and grow sales.

As part of the new strategic plan it was proposed that the Company change its name to CardieX Limited –
reflecting the focus on “excellence in cardiovascular health”.

Following shareholder approval on 28 May, the Company’s name changed officially with the Australian
Securities Investment Commission to CardieX Limited. The ASX listing code also changed from “ACG” to “CDX”.

The effective date for the change of company name and ticker code on the ASX was from commencement of
trading on Monday 18 June 2018.

In order to provide consistency of branding in the existing line of medical devices, the “AtCor” cardiovascular
device business will continue under the AtCor brand as an operating division of the parent company - CardieX.

CARDIEX - ANNUAL REPORT 2018In Q3 and Q4, 2018 the Company will implement a new corporate identity platform that represents CardieX’s
new brand, product and marketing focus.

Management and Board Changes

Mr Craig Cooper was appointed CEO & Managing Director of CardieX with immediate effect from 1 December
2017 and currently holds that position. Former CEO and Managing Director Mr Duncan Ross was appointed
to the newly created role of “EVP & Head of Global Sales” on 1 December 2017. Mr Ross’ employment was
subsequently terminated on 29 June 2018.

Mr Cooper’s appointment is the driving force behind the new strategic direction for the Company. He is focused
on strengthening CardieX as the leader in hypertension management, expanding the Company’s products
into new health professional markets and geographies, and identifying new opportunities for the Company to
expand in high growth health and med-tech areas.

Mr Cooper has founded several highly successful health, digital media, technology and wellness businesses
and has a strong global network and experience across the medical, health technology and mobile sectors.
He was the co-founder of the telecommunications company Boost Mobile USA and is recognised as a
global expert and thought leader in mobile and wireless technology and digital health and Medtech related
businesses.

The Company also appointed Mr. Niall Cairns as a Non-Executive Director with effect from 20 December
2017. Mr Cairns is a Sydney based technology growth investor with a 25-year track record of value creation,
restructuring, and exits in both listed and unlisted companies - having assisted in driving the global growth
of over 50 companies in sectors as diverse as Digital Media, AgTech, Medtech, Consumer Internet, and SAAS
based businesses.

In March 2018, Mr Peter Manley, the Company’s CFO and Company Secretary was terminated. Mr. Jarrod
White of Traverse Accountants was subsequently appointed Company Secretary and CFO to replace Mr
Manley. Mr White is a founding Partner/Director at Traverse Accountants in Sydney and has significant
experience in listed company compliance, transactions, finance, and accounts management.

Dr. Michael O’Rourke, Mr Duncan Ross, and Dr. David Brookes also retired from the Board of Directors during
the year.

Share Placement & Rights Issue

During June 2018, CardieX successfully completed a AU$5 million capital raising initiative which was previously
announced on 23 April. The heavily oversubscribed placement and entitlement offer resulted in the return of
$907,882 entitlement acceptances to shareholders.

The $5M capital raising led to the issue of a total of 250,000,000 new shares and 125,000,000 options on the
following basis:

1. A placement to sophisticated and institutional investors at $0.02 per share which raised $2,375,906.

CARDIEX - ANNUAL REPORT 20182. An investment made by a related party of certain Directors of the Company (Directors: Niall Cairns and

Craig Cooper) raised $1,500,000; and

3. A fully underwritten 1 for 5 non-renounceable entitlement offer at $0.02 per share raised $1,124,094

from Australian and New Zealand shareholders.

Placement and entitlement holder recipients were given one share and free attached new option for every
2 new shares subscribed for and issued. The new listed options trade as CDXO and have an exercise price of
$0.05 with a 30 November 2021 expiry.

The capital raise supports the renewed strategy and vision of CardieX as it focuses on high growth markets
and new health technology opportunities.

Tax Refund

The Company received a refund from the Australian Tax Office under the R&D tax incentive program of
$418,368 on 26 October 2017 (2017: $470,248).

CARDIEX - ANNUAL REPORT 2018DIRECTORS’ REPORT

The Directors of CardieX Limited (the “Company”) (formerly AtCor Medical Holdings Limited) submit the
financial report of the Company for the year ended 30 June 2018, which comprises the results of CardieX
Limited and the entities it controlled during the period (the “Group”).

Review of Operations

The loss for the Group after income tax amounted to $2,961,225 (30 June 2017: $4,363,571).

The Group has generated total revenue of $4,022,554, down from $4,327,836 in the previous year.

Principal Activities

During the year the principal continuing activities of the Group consisted of designing, manufacturing and
marketing medical devices for use in cardiovascular health management.

Dividends

No dividends were paid or declared by the Group since the end of the previous financial year and the Directors
do not recommend dividends be paid for the year ended 30 June 2018.

Significant Changes in the State of Affairs

• The Company changed its name to CardieX Limited – a name that recognises the Company’s legacy
in cardiovascular health while at the same time promoting excellence and expertise in global health
solutions. The name change is part of a complete re-branding of the Company currently being
implemented by executive management;

• The execution of a Development and Collaboration Agreement with Blumio, Inc, a Silicon Valley based

developer of sensor and wearable technology for blood pressure detection. This agreement provides the
framework for the development and integration of the Company’s IP and patents into Blumio’s sensors
and the collaboration of the parties in developing new technology applications for sensor-based detection
of cardiovascular disease; and

• The execution of an agreement between Blumio, Inc and CardieX Limited for an investment in Blumio,
Inc of US$600K (subject to certain capital raise, due diligence and other conditions) that will allow the
Company to obtain up to a 7.5% Equity shareholding in Blumio, Inc.

Likely Developments and Expected Results of Operations

Further information on likely developments in the operations of the Group and the expected results of
operations have not been included in this annual financial report because the Directors believe it would be
likely to result in unreasonable prejudice to the Group.

CARDIEX - ANNUAL REPORT 2018D I R E C T O R ’ S R E P O R T

Matters Subsequent to Year End

• Recruitment of former Masimo, Inc (NASDAQ:MASI US$5b) executive Zihan Lin to head of CardieX’s Asian

strategy with a focus on the Chinese market and new wearable device technologies.

No other significant subsequent event has arisen that significantly affects the operations of the Group.

Directors

The following persons held office as Directors of CardieX Limited at any time during or since the end of the
financial year:

Mr. Donal O’Dwyer

Mr. Niall Cairns, appointed 20 December 2017

Mr. King Nelson

Mr. Craig Cooper, appointed 01 December 2017

Dr. David Brookes, resigned 03 April 2018

Mr. Duncan Ross, resigned 20 December 2017

Dr. Michael O’Rourke, resigned 30 November 2017

Company Secretary and Chief Financial Officer

Mr. Jarrod White has held the role of Company Secretary and Chief Financial Officer since 05 March 2018.

CARDIEX - ANNUAL REPORT 2018D I R E C T O R ’ S R E P O R T

Information on Directors

MR. DONAL O’DWYER

C H A I R M A N

Qualifications:

Appointed:

Experience and expertise:

Other current Directorships:

B.Eng, MBA

07 March 2005

Independent Director of the Group since September 2004 and
Chairman since November 2004. Extensive experience in the
cardiovascular sector. Prior to joining the CardieX Board he was
worldwide President of Cordis Cardiology, the cardiology division of
Johnson & Johnson.

Non-Executive Director for 4 other listed public companies: Cochlear
Ltd, Mesoblast Ltd, Fisher & Paykel Healthcare Corporation Ltd, and nib
Holdings Ltd.

Former Directorships (last 3 years):

None.

Special responsibilities:

• Chairman of the Board.
• Member of Audit and Risk Committee.
• Member of Remuneration and Nomination Committee.

MR. NIALL CAIRNS

N O N - E X E C U T I V E D I R E C T O R

Qualifications:

Appointed:

Experience and expertise:

B.Ec, CA and FAICD

20 December 2017

Mr Cairns was appointed as a Non-Executive Director effective 20
December 2017. Mr Cairns is a Sydney based technology growth
investor with a 25-year track record of value creation, restructuring,
and exits in both listed and unlisted companies having assisted in
driving the global growth of over 50 companies in sectors as diverse
as digital media, AgTech, Medtech, consumer internet, and SAAS based
businesses. Niall is currently the Chairman of Tambla Limited and a
Non-Executive Director of Chant West Holdings and Tru-Test Limited.

Other current Directorships:

Tru-Test Corporation Limited, Kestrel Growth Companies Limited, Chant
West Holdings Limited and Tambla Limited.

Former Directorships (last 3 years):

None.

Special responsibilities:

• Chairman of the Audit and Risk Committee.
• Member of Remuneration and Nomination Committee.

CARDIEX - ANNUAL REPORT 2018

D I R E C T O R ’ S R E P O R T

MR. KING NELSON

N O N - E X E C U T I V E D I R E C T O R

Qualifications:

Appointed:

Experience and expertise:

BA, MBA

13 November 2015

King Nelson was elected to the Board in November 2015. He
brings more than 30 years of diverse experience and expertise with
medical devices. He is a former President and CEO of Uptake Medical
Corporation, a company focused on treatments for emphysema and
lung cancer. Previously, he served as President and CEO of Kerberos
Proximal Solutions, which was acquired by Foxhollow Technologies,
and as President and CEO of Venpro, a heart valve business acquired
by Medtronic. Both of these companies specialised in devices for the
cardiovascular system. Prior to that, he spent 19 years with Baxter
International and American Hospital Supply Corporation in roles of
increasing responsibility that included Division President for Dade
Diagnostics, Bentley Labs, and Baxter’s perfusion services division.

Other current Directorships:

None.

Former Directorships (last 3 years):

Uptake Medical Corporation

Special responsibilities:

• Chair of Remuneration and Nomination Committee.
• Member of Audit and Risk Committee.

MR. CRAIG COOPER

E X E C U T I V E D I R E C T O R , C H I E F E X E C U T I V E O F F I C E R

Qualifications:

Appointed:

Experience and expertise:

B.Ec, LLB (Hons)

1 December 2017

Mr Cooper was appointed as Chief Executive Officer effective 1
December 2017. Mr Cooper has founded multiple successful health,
digital media, technology, and wellness businesses – and was also the
co-founder of the telecommunications company Boost Mobile USA.
He is recognised as a global expert and thought leader in mobile and
wireless technology as well as digital health and med-tech-related
businesses. His venture capital funds have raised over AU$1 billion
in capital and have funded some of the most significant global digital
media, health and technology companies. Prior to relocating to Los
Angeles, Mr Cooper was also the co-founder of NRG Asia-Pacific,
previously one of the largest independent power producers in Australia
with over AU$5 billion in energy assets.

CARDIEX - ANNUAL REPORT 2018

D I R E C T O R ’ S R E P O R T

Other current Directorships:

None.

Former Directorships (last 3 years):

None.

Special responsibilities:

None.

Meetings of Directors

The number of meetings of the Group’s Board of Directors and of each Board Committee held during the
financial year ended 30 June 2018 and the number of meetings attended by each Director were:

Director

Mr. Donal O’Dwyer

Mr. Niall Cairns

Mr. King Nelson

Mr. Craig Cooper

Dr. David Brookes

Mr. Duncan Ross

Dr. Michael O’Rourke

Directors’ Interests

Directors Meetings

Held Whilst in Office

Attended

Information on the Directors’ and their associates’ interests in shares and options of the Company at 30 June
2018 can be found in the Remuneration Report on page 21.

Shares Issued on the Exercise of Options

No shares were issued during the financial year ended 30 June 2018 on the exercise of options.

Environmental Regulations

The Group’s operations are not regulated by any significant environmental regulation under a law of the
Commonwealth or of a State or Territory.

Indemnity and Insurance of Directors and Officers

During the financial year the Group paid premiums in respect of a contract insuring Directors and Executives
against a liability incurred in the ordinary course of business.

Proceedings on Behalf of the Company

No person has applied for leave of court to bring proceedings on behalf of the Company or intervene in any
proceedings to which the Company is a party for the purpose of taking responsibility on behalf of the Company
for all or any part of those proceedings.

The Company was not a party to any such proceedings during the year.

CARDIEX - ANNUAL REPORT 2018D I R E C T O R ’ S R E P O R T

Corporate Governance Statement

A copy of the Corporate Governance Statement has not been disclosed within the Annual Report but is
available on the website www.CardieX.com in accordance with the ASX listing rule 4.10.3.

Declaration by Directors

Before it approved the Company’s 2018 financial statements, the Board was satisfied that the financial
records have been properly maintained and that the financial statements comply with the appropriate
Accounting Standards and give a true and fair view of the financial position and performance of the Group, and
their opinion has been formed on the basis of a sound system of risk management and internal control which
is operating effectively.

Non-audit Services

The Directors received the Auditor’s Independence Declaration under s.307 of the Corporations Act 2001,
which is set out on page 26. The external auditor did not provide non-audit services to the Company during the
year ended 30 June 2018.

Indemnity and Insurance of Auditor

The Company has not, during or since the end of the financial year, indemnified or agreed to indemnify the
auditor of the Company or any related entity against a liability incurred by the auditor.

During the financial year, the Company has not paid a premium in respect of a contract to insure the auditor of
the Company or any related entity.

Officers of the Company Who are Former Partners of BDO

There are no officers of the Company who are former partners of BDO.

Auditor’s Independence Declaration

A copy of the Auditor’s Independence Declaration as required under section 307c of the Corporations Act 2001
is set out on page 26.

Auditor

BDO was elected as auditor at an EGM held on 28 May 2018. BDO holds office in accordance with section 327
of the Corporations Act 2001.

CARDIEX - ANNUAL REPORT 2018REMUNERATION REPORT

This report outlines the remuneration arrangements in place for Directors and Executives of CardieX Limited.
The information in this report has been audited as required by 308(3c) of the Corporations Act 2001.

Principles Used to Determine the Nature and Amount of Remuneration

Non-Executive Directors

Fees and payments to Non-Executive Directors reflect the demands which are made on, and the
responsibilities of, the Directors. Non-Executive Directors’ fees and payments are reviewed annually by the
Board. The Board also refers to external surveys to ensure Non-Executive Directors’ fees and payments are
appropriate and in line with the market. The Chairman’s fees are determined independently to the fees of Non-
Executive Directors based on comparative roles in the external market. The Chairman is not present at any
discussions relating to determination of his own remuneration. Non-Executive Directors are entitled to receive
share options, following approval by the shareholders of CardieX Limited.

Non-Executive Directors’ fees are determined within an aggregate Directors’ fee pool limit, which is
periodically recommended for approval by shareholders. The pool was increased to $360,000 at the 2015
shareholder meeting, excluding share-based payments that are subject to separate shareholder approval.

Executives

The objective of the Group’s Executive reward framework is to ensure reward for performance is competitive
and appropriate for the results delivered. The framework aligns Executive reward with achievement of
strategic objectives and the creation of value for shareholders.

The Board ensures that Executive reward satisfies the following key criteria for good reward governance
practices:

• Competitiveness and reasonableness;

• Acceptability to shareholders;

• Performance linkage / alignment of Executive compensation;

• Transparency; and

• Capital management.

Alignment to shareholders’ interests:

• Has Company growth as a core component of plan design;

• Focuses on sustained long-term growth in shareholder wealth; and

• Attracts and retains high calibre Executives.

CARDIEX - ANNUAL REPORT 2018R E M U N E R A T I O N R E P O R T

Alignment to program participants’ interests:

• Rewards capability and experience;

• Reflects competitive reward for contribution to growth in company value;

• Provides a clear structure for earning rewards; and

• Provides recognition for contribution.

The Chief Executive Officer has been issued with 24 million performance rights in the year that will vest across
3 equal tranches subject to incremental improvements in the Company’s share price. All other Directors and
key management personnel are on fixed remuneration as befitting their non-executive status.

Details of the nature and amount of each element of the emoluments of each Director of CardieX Limited are
set out below.

Directors

Names and positions held of key management personnel in office at any time during the financial year are:

Mr. Donal O’Dwyer

Non-Executive Director and Chairman

Mr. Niall Cairns

Mr. King Nelson

Non-Executive Director (appointed 20 December 2017)

Non-Executive Director

Mr. Craig Cooper

CEO and Executive Director (appointed 1 December 2017)

Dr. David Brookes

Non-Executive Director (resigned 03 April 2018)

Mr. Duncan Ross

Executive Director (resigned 20 December 2017)

Dr. Michael O’Rourke

Non-Executive Director (resigned 30 November 2017)

CARDIEX - ANNUAL REPORT 2018
R E M U N E R A T I O N R E P O R T

Key Management Personnel Compensation

Salary and Directors
fees

Performance Rights
Issued

Post-Employment
Benefits

2018

Mr. Donal O’Dwyer

Mr. Niall Cairns

Mr. King Nelson

Mr. Craig Cooper

Dr. David Brookes

Mr. Duncan Ross

Dr. Michael O’Rourke

Total Compensation

2017

Mr. Donal O’Dwyer

Mr. King Nelson

Dr. David Brookes

Mr. Duncan Ross

Dr. Michael O’Rourke

Total Compensation

50,228

28,000

27,955

225,863

18,949

179,830

9,513

540,338

68,750

37,182

37,500

429,619

31,250

604,301

4,466

4,772

3,551

13,439

904

22,666

16,597

11,490

69,688

11,490

120,755

Shares Held by Key Management Personnel and Their Associates

Total

55,000

28,000

27,955

230,329

22,500

193,269

10,417

567,470

85,347

48,672

48,990

499,307

42,740

725,056

Balance
30 June 2018

12,178,627

Balance
01 July 20171

6,067,517

3,000,0001

153,846

-1

1,469,264

4,603,052

10,641,396

25,935,075

Share split

Additions

6,111,110

75,000,0002

78,000,000

75,000,0002

555,555

153,846

75,000,000

2,024,8193

4,603,0523

925,925

11,567,3213

157,592,590

183,527,665

Shares held at date of appointment.

Shares acquired by Mr Cairns and Mr Cooper in the year are indirectly held by C2 Ventures, in which Mr Cairns and Mr Cooper are Directors.
These shares are subject to the Restriction Agreement and Deed of Undertaking as approved by members at the Extraordinary General Meeting
held on 28 May 2018.

Mr. Donal O’Dwyer

Mr. Niall Cairns

Mr. King Nelson

Mr. Craig Cooper

Dr. David Brookes

Mr. Duncan Ross

Dr. Michael O’Rourke

Total

3. Held at date of resignation.

CARDIEX - ANNUAL REPORT 2018R E M U N E R A T I O N R E P O R T

Options Held by Key Management Personnel and Their Associates

Donal O’Dwyer

Niall Cairns

King Nelson

Craig Cooper

David Brookes

Duncan Ross

Michael O’Rourke

Total

Balance
01 July 20171

650,000

-1

450,000

-1

450,000

3,100,000

450,000

5,100,000

Share split

Additions

2,500,000

37,500,0002

77,500,000

Balance
30 June 2018

3,150,000

37,500,000

450,000

37,500,000

450,0003

3,100,0003

450,0003

82,600,000

1. Options held at date of appointment.

2. Options acquired by Mr Cairns and Mr Cooper in the year are indirectly held by C2 Ventures, in which Mr Cairns and Mr Cooper are Directors.
These options are subject to the Restriction Agreement and Deed of Undertaking as approved by members at the Extraordinary General
Meeting held on 28 May 2018.

3. Held at date of resignation.

4. Options acquired by key management personnel and their associates in the year related are free attaching options on shares purchased.

Performance Rights Held Key Management Personnel and Their Associates

Mr Craig Cooper holds 24 million performance rights which vest subject to a set of milestones as follows:

Tranche 1

Tranche 2

Tranche 3

Number of performance rights

Will vest if 30 Day VWAP
exceeds:

Expiry Date of Performance
Milestone

8 million

$0.05

$0.08

$0.12

28/05/2021

Employment Agreements

Remuneration and other terms of employment for the CEO and the other key management personnel are
formalised in employment agreements. Each of these agreements provide for the provision of performance
related cash bonuses, other benefits including health insurance and car allowances, and participation, when
eligible, in the CardieX Limited Employee Share Option Plan. Other major provisions of the agreements relating
to remuneration are set out below.

All contracts with Executives may be terminated early by either party with variable notice periods, subject to
termination payments as detailed below.

CARDIEX - ANNUAL REPORT 2018R E M U N E R A T I O N R E P O R T

Craig Cooper – Chief Executive Officer

• Agreement commenced on 1 December 2017.

• Base salary of US$300,000 per annum.

• Reimbursement for reasonable administrative expenses incurred in running the US business, paid on a

monthly basis up to US$5,000 per month.

Niall Cairns – Non-Executive Director

• Agreement commenced with an effective date of 1 March 2018.

• Monthly consulting fee for strategic review and consulting services of AU$7,000 per month.

• Reimbursement for reasonable administrative expenses incurred.

Loans to Directors and Key Management Personnel

During the year the Company entered into a Deed of Undertaking with C2 Ventures Pty Limited, a related party
of Mr Niall Cairns and Mr Craig Cooper.

Under the Deed of Undertaking C2 Ventures Pty Limited subscribed for 75,000,000 shares and 37,500,000
free attaching options on a one for two basis on the same terms as offered to shareholders under the
entitlements issue. Under the Deed of Undertaking C2 Ventures Pty Limited is required to pay the total
subscription monies ($1,500,000) in full before 30 November 2018.

The arrangement was approved by shareholders at the Extraordinary General Meeting held on 28 May 2018.

There were no other loans made to Directors or key management personnel of the Company and the Group
during the period commencing at the beginning of the financial year and up to the date of this report.

Signed in accordance with a resolution of the Board of Directors, made pursuant to s.298(2) of the
Corporations Act 2001.

Donal O’Dwyer
Chairman
Sydney, 31 August 2018

CARDIEX - ANNUAL REPORT 2018
AUDITOR’S INDEPENDENCE DECLARATION

Tel: +61 2 9251 4100
Fax: +61 2 9240 9821
www.bdo.com.au

Level 11, 1 Margaret St
Sydney NSW 2000
Australia

DECLARATION OF INDEPENDENCE BY GRANT SAXON TO THE DIRECTORS OF CARDIEX LIMITED

As lead auditor of CardieX Limited for the year ended 30 June 2018, I declare that, to the best of my
knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of the Corporations Act 2001 in

relation to the audit; and

2. No contraventions of any applicable code of professional conduct in relation to the audit.

This declaration is in respect of CardieX Limited and the entities it controlled during the period.

Grant Saxon
Partner

BDO East Coast Partnership

Sydney, 31 August 2018

BDO East Coast Partnership ABN 83 236 985 726 is a member of a national association of independent entities which are all members of BDO Australia Ltd
ABN 77 050 110 275, an Australian company limited by guarantee. BDO East Coast Partnership and BDO Australia Ltd are members of BDO International Ltd,
a UK company limited by guarantee, and form part of the international BDO network of independent member firms. Liability limited by a scheme approved
under Professional Standards Legislation, other than for the acts or omissions of financial services licensees.

CARDIEX - ANNUAL REPORT 2018CONSOLIDATED STATEMENT OF PROFIT
OR LOSS AND OTHER COMPREHENSIVE
INCOME

For Year Ended 30 June 2018

Note

2018

4,006,091

16,463

4,022,554

418,368

4,440,922

(881,770)

(133,308)

(58,572)

(2,433,348)

(1,543,420)

(277,702)

(1,716,976)

(15,348)

(341,703)

(2,961,225)

2017

4,327,283

553

4,327,836

473,124

4,800,960

(1,016,673)

(4,074,219)

(1,475,724)

(179,979)

(2,021,775)

(396,161)

(4,363,571)

(2,961,225)

(4,363,571)

423,940

(2,537,285)

371,990

(3,991,581)

(1.0)

(2.0)

Sales revenue

Other revenue

Other income

Total income

Cost of sales

Bad debts expense

Inventory impairment expense

Marketing and sales expense

Product development and regulatory expense

Occupancy expense

Administration expense

Interest expense

Foreign exchange loss

Loss before income tax expense

Income tax expense

Loss attributable to members of the parent entity

Other comprehensive income

Items that will be reclassified subsequently to profit or loss when specific
conditions are met:

Exchange differences on translating foreign operations

Total comprehensive loss for the period

Basic earnings per share (cents)

Diluted earnings per share (cents)

These financial statements should be read in conjunction with the accompanying notes.

CARDIEX - ANNUAL REPORT 2018CONSOLIDATED STATEMENT OF
FINANCIAL POSITION

As at 30 June 2018

Assets

Current assets

Cash and cash equivalents

Trade and other receivables

Inventory

Other

Total current assets

Non-current assets

Property, plant and equipment

Financial assets

Total non-current assets

Total assets

Liabilities

Current liabilities

Trade and other payables

Provisions

Borrowings

Total current liabilities

Non-current liabilities

Provisions

Total non-current liabilities

Total liabilities

Net assets

Equity

Contributed equity

Reserves

Accumulated losses

Total equity

These financial statements should be read in conjunction with the accompanying notes.

Note

2018

2017

2,736,517

1,113,219

490,362

1,774,152

6,114,250

97,079

202,578

299,657

6,413,907

1,469,402

115,028

185,000

1,769,430

48,264

1,817,694

677,917

1,582,453

463,633

86,668

2,810,671

149,422

2,960,093

1,404,991

121,910

1,526,901

104,706

1,631,607

4,596,213

1,328,486

46,832,833

1,571,498

41,126,573

2,327,448

(43,808,118)

(42,125,535)

4,596,213

1,328,486

CARDIEX - ANNUAL REPORT 2018CONSOLIDATED STATEMENT OF
CHANGES IN EQUITY

For Year Ended 30 June 2018

Balance at 1 July 2016

Loss for the year

Other comprehensive income

Total comprehensive income for the year

Transactions with equity holders in their
capacity as owners.

Capital placement & rights issue (net)

Options exercised

Options issued

Note

Shares on Issue

Reserves

Accumulated
losses

Total

39,126,899

1,775,840

(37,761,964)

3,140,775

1,756,874

242,800

1,999,674

(4,363,571)

371,990

179,618

371,990

(4,363,571)

(3,991,581)

1,756,874

242,800

179,618

2,179,292

Balance at 30 June 2017

41,126,573

2,327,448

(42,125,535)

1,328,486

Balance at 1 July 2017

Loss for the year

Other comprehensive income

Total comprehensive income for the year

Transactions with equity holders in their
capacity as owners.

Capital placement (net)

Options issued

Options expired

Balance at 30 June 2018

41,126,573

2,327,448

(42,125,535)

1,328,486

(2,961,225)

423,940

(2,961,225)

(2,537,285)

5,706,260

98,752

(1,278,642)

1,278,642

5,706,260

98,752

46,832,833

1,571,498

(43,808,118)

4,596,213

These financial statements should be read in conjunction with the accompanying notes.

CARDIEX - ANNUAL REPORT 2018CONSOLIDATED STATEMENT OF CASH
FLOWS

Note

2018

2017

4,316,651

(6,959,455)

(2,642,804)

603,369

16,463

(15,348)

4,790,031

(8,326,462)

(3,536,431)

470,248

553

(2,038,320)

(3,065,630)

(4,916)

(202,578)

(207,494)

4,304,029

2,058,215

677,917

385

2,736,517

(17,245)

1,999,674

(1,083,201)

1,773,950

(12,832)

677,917

For Year Ended 30 June 2018

Cash flows from operating activities

Receipts from customers

Payments to suppliers and employees

Other income

Interest received

Interest paid

Net cash used in operating activities

Cash flows from investing activities

Payments to acquire property, plant and equipment

Payments for financial assets

Net cash used in investing activities

Cash flows from financing activities

Net proceeds from shares issued

Net cash provided by financing activities

Net increase/(decrease) in cash held

Cash and cash equivalents at beginning of financial year

Effects of foreign currency exchange

Cash and cash equivalents at end of financial year

These financial statements should be read in conjunction with the accompanying notes.

CARDIEX - ANNUAL REPORT 2018NOTES TO THE CONSOLIDATED
FINANCIAL STATEMENTS

NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The financial report includes the consolidated financial statements and notes of CardieX Limited and controlled
entities (‘Consolidated Group’ or ‘Group’). CardieX Limited changed its name from AtCor Medical Holdings
Limited on 28 May 2018 following a special resolution at an Extraordinary General Meeting of shareholders
on the same day. The separate financial statements and notes of CardieX Limited as an individual parent
entity have not been presented within the financial report as permitted by the Corporations Act 2001. CardieX
Limited is a for-profit entity.

The financial statements were authorised for issue on 31 August 2018 by the Directors of the Company.

Basis of Preparation

The financial report is a general purpose financial report that has been prepared in accordance with Australian
Accounting Standards, Australian Accounting Interpretations, other authoritative pronouncements of the
Australian Accounting Standards Board (“AASB”) and the Corporations Act 2001.

Australian Accounting Standards set out accounting policies that the AASB has concluded would result in
a financial report containing relevant and reliable information about transactions, events and conditions to
which they apply. Compliance with Australian Accounting Standards ensures that the financial statements and
notes also comply with International Financial Reporting Standards. Material accounting policies adopted in
the preparation of this financial report are reported below. They have been consistently applied unless stated
otherwise. All applicable new Accounting Standards have been adopted for the year ended 30 June 2018
unless otherwise stated and their adoption did not have a significant impact on the financial performance or
position of the consolidated entity.

The financial report has been prepared on an accruals basis and is based on historical costs, modified, where
applicable, by the measurement at fair value of selected non-current assets, financial assets and financial
liabilities.

Accounting Policies

a. Going Concern

The financial statements have been prepared on the going concern basis, which contemplates continuity
of normal business activities and the realisation of assets and the discharge of liabilities in the normal
course of business.

At the date of signing, the Directors have assessed that there is a material uncertainty related to going
concern that may cast significant doubt over the ability of the Group to continue as a going concern given

CARDIEX - ANNUAL REPORT 2018c. Going Concern (Cont.)

that the Group incurred a loss after tax of $2,961,225 (2017: $4,363,571) and had net cash outflows from
operating activities of $2,038,320 for the year ended 30 June 2018 (2017: $3,065,630). As a result of
these conditions the Group may be unable to realise its assets and discharge its liabilities in the normal
course of business.

The Directors believe that there are reasonable grounds that the Group will be able to continue as a going
concern, after consideration of the following factors:

• The Group has cash and cash equivalents of $2,736,517 as at 30 June 2018 (2017: $677,917). As
at that date, the Group had net current assets of $4,344,820 (2017: $1,283,770) and net assets of
$4,596,213 (2017: $1,328,486). The Group has performed a cash flow forecast, and determined that
it has adequate cash resources in place to fund its operations for the next 12 months, even in the
absence of obtaining additional funding;

•

If required, the Group has the ability to continue to raise additional funds on a timely basis pursuant
to the Corporations Act 2001. The Group has raised in excess of $4 million in the previous 12-month
reporting period and the Directors have no reason to believe that it will not be able to continue to
source equity or alternative funding if required; and

• The Group has the ability to scale back a significant portion of its development activities if required.

Accordingly, the Directors believe that the Group will be able to continue as a going concern, and that it is
appropriate to adopt the going concern basis in the preparation of the financial report.

b. Principles of Consolidation

A controlled entity is any entity CardieX Limited has the power to control the financial and operating
policies of so as to obtain benefits from its activities.

A list of controlled entities is contained in Note 12 to the financial statements. All controlled entities have a
30 June 2018 financial year-end for this current year.

As at the reporting date, the assets and liabilities of all controlled entities have been incorporated into the
consolidated financial statements as well as their results for the year ended.

All inter-company balances and transactions between entities in the Group, including any unrealised
profits or losses, have been eliminated on consolidation. Accounting policies of subsidiaries have been
changed where necessary to ensure consistencies with those policies applied by the Company.

Where controlled entities have entered or left the Group during the year, their operating results have been
included/excluded from the date control was obtained or until the date control ceased.

c. Revenue Recognition

Revenue is recognised when it is probable that the economic benefit will flow to the consolidated entity
and the revenue can be reliably measured. Revenue is measured at the fair value of the consideration
received or receivable.

CARDIEX - ANNUAL REPORT 2018
c. Revenue Recognition (Cont.)

Sale of goods
Sales of goods revenue is recognised at the point of sale, which is where the customer has taken delivery
of the goods, the risks and rewards are transferred to the customer and there is a valid sales contract.
Amounts disclosed as revenue are net of sales returns and trade discounts.

Lease sales
The Group earned rental income from operating leases of goods. Rental income is recognised on a
straight-line basis over the term of the lease. At the end of the financial year, the Group no longer provides
operating leases to customers.

Finance lease sales
The economic ownership of a leased asset is transferred to the lessee if the lessee bears substantially
all the risks and rewards of ownership of the leased asset. Where the Group is a lessor in this type of
arrangement, sales revenue recognised at the inception of the lease at the fair value of the leased asset or,
if lower, the present value of the minimum lease payments.

Government grants
Revenue from the research and development tax incentive scheme is recognised on receipt.

Other revenue
Other revenue is recognised when it is received or when the right to receive payment is established.

d. Plant and Equipment

Each class of property, plant and equipment is carried at cost or fair value less, where applicable, any
accumulated depreciation and impairment losses.

Depreciation
The depreciable amount of all fixed assets is depreciated on a straight-line basis over their useful lives to
the Group commencing from the time the asset is held ready for use.

The useful lives used for depreciable assets are:

Class of fixed asset
Manufacturing plant and equipment
Furniture, fixtures and equipment
Devices leased to customers

Useful lives
3 - 10 years
3 – 5 years
3 – 4 years

The assets’ residual values and useful lives are reviewed, and adjusted if appropriate, at each balance
sheet date.

An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying
amount is greater than its estimated recoverable amount.

Gains and losses on disposals are determined by comparing proceeds with the carrying amount. These gains
and losses are included in the Statement of Profit or Loss and Other Comprehensive Income sections.

CARDIEX - ANNUAL REPORT 2018

Impairment of Assets
At each reporting date, the Group reviews the carrying values of its tangible assets to determine whether
there is any indication that those assets have been impaired. If such an indication exists, the recoverable
amount of the asset, being the higher of the asset’s fair value less costs to sell and value in use, is
compared to the asset’s carrying value. Any excess of the asset’s carrying value over its recoverable
amount is expensed to the Statement of Profit or Loss and Other Comprehensive Income sections.

Where it is not possible to estimate the recoverable amount of an individual asset, the Group estimates
the recoverable amount of the cash-generating unit to which the asset belongs.

f. Financial Instruments

Recognition, initial measurement and derecognition

Financial assets and financial liabilities are recognised when the Group becomes a party to the contractual
provisions of the financial instrument, and are measured initially at fair value adjusted by transactions
costs, except for those carried at Fair Value Through Profit or Loss, which are measured initially at fair
value. Subsequent measurement of financial assets and financial liabilities are described below.

Financial assets are derecognised when the contractual rights to the cash flows from the financial asset
expires, or when the financial asset and all substantial risks and rewards are transferred. A financial liability
is derecognised when it is extinguished, discharged, cancelled or expired.

Classification and subsequent measurement of financial assets

For the purpose of subsequent measurement, financial assets other than those designated and effective
as hedging instruments are classified into the following categories upon initial recognition:

• Loans and receivables

• Financial assets at Fair Value Through Profit or Loss (FVTPL)

• Held-To-Maturity (HTM) investments

All financial assets, except for those at FVTPL, are subject to review for impairment at least at each
reporting date to identify whether there is any objective evidence that a financial asset or a group of
financial assets is impaired. Different criteria to determine impairment are applied for each category of
financial assets, which are described below.

All income and expenses relating to financial assets that are recognised in profit or loss are presented
within finance costs, finance income or other financial items, except for impairment of trade receivables
which is presented within other expenses.

g. Employee Benefits

Provision is made for the Group’s liability for employee benefits arising from services rendered by
employees to balance date. Employee benefits that are expected to be settled within one year have been
measured at the amounts expected to be paid when the liability is settled. Employee benefits payable later
than one year have been measured at the present value of the estimated future cash flows to be made for
those benefits. Those cash flows are discounted using market yields on national government bonds with
terms to maturity that match the expected timing of the cash flows.

CARDIEX - ANNUAL REPORT 2018
h. Equity-Settled Compensation

There has been no equity based compensation with the exception of that described in Note 18. The capital
subscribed to as per this note was acquired at fair value at the time of purchase.

Options issues have their fair value determined with reference to an approved valuation methodology,
such as the Black-Scholes valuation method. On issue, the fair value of an option is taken to the income
statement as equity settled compensation, with a corresponding credit to the options reserve. This is then
disclosed as other comprehensive income in the Statement of Comprehensive Income section to show
other net profit position of the Group from a third party perspective.

Shares have their value determined using the direct method of share price at date of issue multiplied by
the number of shares issued.

i. Cash and Cash Equivalents

Cash and cash equivalents include cash on hand, deposits held at call with banks and other short-term
highly liquid investments with original maturities of three months or less.

j. Trade and Other Receivables

Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using
the effective interest method, less any provision for impairment. Trade receivables are generally due for
settlement within 30 days.

Collectability of trade receivables is reviewed on an ongoing basis. Debts which are known to be
uncollectable are written off by reducing the carrying amount directly. A provision for impairment of trade
receivables is raised when there is objective evidence that the consolidated entity will not be able to
collect all amounts due according to the original terms of the receivables. Significant financial difficulties
of the debtor, probability that the debtor will enter bankruptcy or financial reorganisation and default or
delinquency in payments (more than 60 days overdue) are considered indicators that the trade receivable
may be impaired.

Other receivables are recognised at amortised cost, less any provision for impairment.

Inventories

Inventories are stated at the lower of cost and net realisable value. Cost includes all expenses directly
attributable to the manufacturing process as well as suitable portions of related production overheads,
based on normal operating capacity. Costs are assigned using the first in, first out cost formula. Net
realisable value is the estimated selling price in the ordinary course of business less any applicable selling
expenses.

l. Trade and Other Payables

Liabilities for creditors and other amounts are carried at amortised cost, which is the present value of the
consideration to be paid in the future for goods and services received, whether or not billed to the Group.
The carrying period is dictated by market conditions but is generally less than 30 days.

CARDIEX - ANNUAL REPORT 2018m. Provisions

The Group’s provisions consist of short-term and long-term employee benefits.

Short-term employee benefits
Short-term employee benefits are benefits, other than termination benefits, that are expected to be
settled wholly within 12 months after the end of the period in which the employees render the related
service. Examples of such benefits include wages and salaries, non-monetary benefits and accumulating
sick leave. Short-term employee benefits are measured at the undiscounted amounts expected to be paid
when the liabilities are settled.

Other long-term employee benefits
The Group’s liabilities for annual leave and long service leave are included in other long term benefits
as they are not expected to be settled wholly within 12 months after the end of the period in which the
employees render the related service. They are measured at the present value of the expected future
payments to be made to employees. The expected future payments incorporate anticipated future wage
and salary levels, experience of employee departures and periods of service, and are discounted at rates
determined by reference to market yields at the end of the reporting period on high quality corporate
bonds that have maturity dates that approximate the timing of the estimated future cash outflows. Any
re-measurements arising from experience adjustments and changes in assumptions are recognised in
profit or loss in the periods in which the changes occur. The Group presents employee benefit obligations
as current liabilities in the statement of financial position if the Group does not have an unconditional
right to defer settlement for at least 12 months after the reporting period, irrespective of when the actual
settlement is expected to take place.

Income Tax

The income tax expense or benefit for the period is the tax payable on that period’s taxable income based
on the applicable income tax rate for each jurisdiction, adjusted by the changes in deferred tax assets and
liabilities attributable to temporary differences, unused tax losses and the adjustment recognised for prior
periods, where applicable.

CardieX Limited and its wholly owned Australian controlled entities have implemented the tax
consolidation legislation as of July 1, 2005.

The head entity, CardieX Limited, and the controlled entities in the tax Consolidated Group account for
their own current and deferred tax amounts. These amounts are measured as if each entity in the tax
Consolidated Group continues to be a standalone taxpayer in its own right.

o. Finance Costs

Finance costs directly attributable to the acquisition, construction or production of assets that necessarily
take a substantial period of time to prepare for their intended use or sale, are added to the cost of those
assets, until such time as the assets are substantially ready for their intended use or sale.

All other finance costs are recognised in the period in which they are incurred.

CARDIEX - ANNUAL REPORT 2018p. Goods and Services Tax (GST)

Revenue, expenses and assets are recognised net of the amount of GST, except where the amount of GST
incurred is not recoverable from the Australian Tax Office. In these circumstances the GST is recognised as
part of the cost of acquisition of the asset or as part of an item of the expense. Receivables and payables
in the statement of financial position are shown inclusive of GST.

Cash flows are presented in the statement of cash flows on a gross basis, except for the GST components
of investing and financing activities, which are disclosed as operating cash flows. There is provision made
in the statement of cash flows to disclose the applicable GST refunds/payments that have been remitted
to the ATO to accurately show the cash position of CardieX Limited.

q. Foreign Currency Translation

Functional currency
Items included in the financial statements of the Group’s operations are measured using the currency of
the primary economic environment in which it operates (‘the functional currency’).

The functional currency of the Company and controlled entities registered in Australia is Australian dollars
(AU$).

The functional currency of AtCor Medical Inc is United States dollars (US$).

Foreign currency transactions are translated into the functional currency using the exchange rates ruling
at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are
retranslated at the rate of exchange ruling at the end of the reporting period. Foreign exchange gains and
losses resulting from settling foreign currency transactions, as well as from restating foreign currency
denominated monetary assets and liabilities, are recognised in profit or loss, except when they are
deferred in other comprehensive income as qualifying cash flow hedges or where they relate to differences
on foreign currency borrowings that provide a hedge against a net investment in a foreign entity.

Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates
at the date when fair value was determined.

Presentation currency
The financial statements are presented in Australian dollars, which is the Group’s presentation currency.

Functional currency balances are translated into the presentation currency using the exchange rates at the
balance sheet date. Value differences arising from movements in the exchange rate is recognised in the
Statement of Comprehensive Income.

Issued Capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares
or options are shown in equity as a deduction, net of tax, from the proceeds.

s. Foreign Currency Translation Reserve

Foreign currency translation reserve comprises foreign currency translation differences arising on the
translation of financial statements of the Group’s foreign entities into $AUD.

CARDIEX - ANNUAL REPORT 2018t. Earnings Per Share

Basic earnings per share is calculated by dividing the profit or loss attributable to the owners of the Group
excluding any costs of servicing equity other than ordinary shares, by the weighted average number of
ordinary shares outstanding during the financial year.

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to
take into account the after income tax effect of interest and other financial costs associated with dilutive
potential ordinary shares and the weighted average number of shares assumed to have been issued for no
consideration in relation to the dilutive potential ordinary shares.

u. Comparative Figures

Comparative figures have been derived from the financial statements for CardieX Limited for the year
ended 30 June 2018, and changes in presentation are made where necessary to comply with Accounting
Standards.

v. Critical Accounting Estimates and Judgements

The Directors evaluate estimates and judgements incorporated into the financial report based on historical
knowledge and best available current information. Estimates assume a reasonable expectation of future
events and are based on current trends and economic data, obtained both externally and within the Group.

Valuation of options issued
The Company issued 2,500,000 options to the service providers in 2018 financial year as disclosed in Note
20. There is significant judgement in relation to the assumptions used in the Black Scholes Option pricing
models. Judgement is required with regards to the fair value of the shares at the issue date, the market
volatility, the expected exercise period, and a number of other inputs into the models.

Recovery of deferred tax assets
Deferred tax assets are recognised for deductible temporary differences where management considers
that it is probable that future taxable profits will be available to utilise those temporary differences.
Significant judgement is required on the part of management and the Board to determine the amount of
deferred tax assets that can be recognised, based upon the likely timing and the level of future taxable
profits over the future years together with future tax planning strategies. Management and the Board
have determined not to raise any deferred tax assets which are estimated at $9,765,832 during the full
year ended 30 June 2018 so as to enable the Board to determine more reliably the probability of utilising
these tax assets in the foreseeable future.

Impairment – general
The Group assesses impairment at the end of each reporting period by evaluating conditions and events
specific to the Group that may be indicative of impairment triggers. Recoverable amounts of relevant
assets are reassessed using value-in-use calculations which incorporate various key assumptions.

Platform and product development costs
Platform and development costs have been expensed in the year in which incurred. These amounts
have not been capitalised on the basis that the Directors consider that the expenditures do not meet the
recognition criteria of development costs as defined by AASB 138 Intangible Assets.

CARDIEX - ANNUAL REPORT 2018w. New and Revised Accounting Standards Not Yet Mandatory or Early Adopted

At the date of authorisation of the financial statements the following new standards and interpretations
have not been early adopted. The below are a list of the standards.

At reporting date the Group had not made a formal assessment of the likely impact of the new Accounting
Standards.

Standard/Interpretation

Effective for Annual Reporting
periods beginning on or after

Initially applied in
the financial year
ending

Likely impact on initial application

AASB 9 ‘Financial
Instruments’ (December
2014)

AASB 15 Revenue from
Contracts with Customers

1 January 2018

30 June 2019

1 January 2018

30 June 2019

AASB 16 Leases

1 January 2019

30 June 2020

The Group has not yet assessed the
impact of this accounting Standard on its
transactions and balances.

NOTE 2: REVENUE

Sales revenue

Sale of goods

Other revenue

Interest received

Total revenue

NOTE 3: OTHER INCOME

R&D tax concession received from the Australian Tax Office (ATO)

Other

2018

4,006,091

16,463

4,022,554

2018

418,368

2017

4,327,283

553

4,327,836

2017

470,248

2,876

473,124

CARDIEX - ANNUAL REPORT 2018NOTE 4: EXPENSES

Loss before income tax includes the following specific expenses:

Depreciation on plant and equipment

Employee benefit expense

Rental expense relating to operating leases

Research and development

NOTE 5: INCOME TAX EXPENSE

Loss from continuing operations before income tax expense

Prima facie tax benefit on loss from ordinary activities before income tax at 27.5%
(2017: 27.5%):

Add tax effect of:

— Other non-allowable items

Subtotal

Less tax effect of:

— Items not assessable for taxation

— Items deductible for taxation but not accounting

Differences in overseas tax rates

Benefit of tax losses and temporary differences not recognised

Income tax expense

2018

61,174

3,723,253

198,828

790,143

2018

(2,961,225)

(814,337)

291,553

(522,784)

(115,052)

(166,603)

130,597

673,842

2017

84,990

5,176,595

179,979

1,089,301

2017

(4,363,571)

(1,199,982)

49,664

(1,150,318)

(182,874)

451,061

882,131

The Group has carry forward tax losses, calculated according to Australian income tax legislation of
$35,512,116 (2017: $33,069,324), which will be deductible from future assessable income provided that
income is derived, and:

a. The Company and its controlled entities carry on a business of, or a business that includes software

development in Australia; and

b. No change in tax legislation adversely affects the Group and its controlled entities in realising the benefit

from the deduction for the losses.

The benefit of these losses will only be recognised where it is probable that future taxable profit will be
available against which the benefits of the deferred tax asset can be utilised. Deferred tax assets are
estimated but not recognised at $9,765,832 at 30 June 2018 (2017: $9,094,064).

CardieX Limited and its wholly-owned Australian controlled entities are consolidated for income tax purposes.
The accounting policy in relation to this legislation is set out in Note 1(n).

As at the date of this report the entities in the tax consolidation group had not entered into a tax sharing
agreement. No compensation has been received or paid for any current tax payable or deferred tax assets
relating to tax losses assumed by the parent entity since implementation of the tax consolidation regime.

CARDIEX - ANNUAL REPORT 2018NOTE 6: AUDITOR REMUNERATION

Remuneration of the auditor of the Group for:

Audit services for the financial year - PWC

Audit services for the financial year - BDO

Total

NOTE 7: EARNINGS PER SHARE

a. Reconciliation of earnings:

Loss after tax

b. Weighted average number of ordinary shares outstanding during the year
used in calculating EPS

c. Basic EPS

d. Diluted EPS

NOTE 8: CASH AND CASH EQUIVALENTS

Cash at bank and on hand

Total

NOTE 9: TRADE AND OTHER RECEIVABLES

CURRENT

Trade receivables

Less: Provision for doubtful debts (a)

Other receivables

Total current assets

2018

48,307

60,000

108,307

2017

119,835

2018

2017

(2,961,225)

(4,363,571)

No.

294,429,146

221,263,936

Cents

(1.0)

2018

2,736,517

2018

1,222,078

(108,859)

1,113,219

Cents

(2.0)

2017

677,917

2017

1,554,875

(16,842)

1,538,033

44,420

1,582,453

CARDIEX - ANNUAL REPORT 2018NOTE 9: TRADE AND OTHER RECEIVABLES (CONT.)

Impaired trade receivables

Trade receivables and other receivables are non-interest bearing and are generally on 30 day terms. A provision
for impairment loss is recognised when there is objective evidence that an individual receivable is impaired.

As at 30 June 2018 current trade receivables of the Group with a nominal value of $53,600 (2017: $16,842)
were fully impaired.

At 1 July

Provision for impairment recognised during the year

Receivables written off during the year as uncollectible

At 30 June

b. Fair value, foreign exchange and credit risk

2018

16,842

133,308

(41,291)

108,859

2017

45,765

15,387

(44,310)

16,842

Due to the short-term nature of these receivables, their carrying amount is assumed to approximate their
fair value. The maximum exposure to credit risk at the reporting date is the carrying amount of each class of
receivables mentioned above. Refer to Note 24 for more information on the risk management policy of the
Group, the credit quality and foreign currency risk of the Group’s trade receivables.

Interest rate risk

Detail regarding interest rate risk exposure is disclosed in Note 24.

NOTE 10: INVENTORIES

Raw materials and stores at cost

Finished goods at cost

Provision for inventory impairment

2018

334,506

214,428

(58,572)

490,362

2017

359,633

104,000

463,633

Inventories recognised as expense during the year ended 30 June 2018 amounted to $256,059 (2017: $411,714). A charge of
$58,572 was taken to write-off obsolete inventories in the year ended 30 June 2018 (2017: $nil).

NOTE 11: OTHER CURRENT ASSETS

Prepayments

Finance lease receivable

Amounts due from related parties

Other

2018

63,232

159,252

1,500,000

51,668

1,774,152

2017

63,742

22,926

86,668

CARDIEX - ANNUAL REPORT 2018NOTE 11: OTHER CURRENT ASSETS (CONT.)

Amounts Due from Related Parties

On 31 May 2018, the Company issued 75 million shares to C2 Ventures, in which Mr Cairns and Mr Cooper are
Directors. Consideration for these shares remains payable and these shares are held on escrow and subject
to a holding lock until the full amount of consideration of $1.5 million is received, anticipated to be November
2018. Interest is accruable on the balance outstanding at the NAB’s published rate for term deposits of 6
months.

Country of
Incorporation

Percentage
Owned (%)*

2018

2017

Australia

USA

100

Manufacturing
plant and
equipment

Furniture,
fixtures and
equipment

Devices leased
to customers

120,648

288

(32,408)

88,528

94,127

13,041

(3,103)

(49,539)

54,526

508,210

(419,682)

88,528

748,922

(694,396)

54,526

5,413

3,916

(3,043)

6,368

9,443

(3,075)

6,368

Total

220,188

17,245

(3,021)

(84,990)

149,422

1,266,575

(1,117,153)

149,422

NOTE 12: CONTROLLED ENTITIES

Controlled Entities Consolidated

Parent Entity

CardieX Limited

Subsidiaries of CardieX Limited

AtCor Medical Pty Limited

AtCor Medical Inc

* Percentage of voting power is in proportion to ownership

NOTE 13: PLANT AND EQUIPMENT

Year Ended 30 June 2017

Opening net book amount

Additions

Exchange differences

Depreciation charge

Closing net book amount

At 30 June 2017

Cost

Accumulated depreciation

Net book amount

CARDIEX - ANNUAL REPORT 2018NOTE 13: PLANT AND EQUIPMENT (CONT.)

Year Ended 30 June 2018

Opening net book amount

Additions

Exchange differences

Depreciation charge

Closing net book amount

At 30 June 2018

Cost

Accumulated depreciation

Net book amount

NOTE 14: TRADE AND OTHER PAYABLES

Manufacturing
plant and
equipment

Furniture,
fixtures and
equipment

Devices leased
to customers

Total

88,528

469

2,437

(26,207)

65,227

54,526

6,368

878

3,569

149,422

4,916

189

1,289

3,915

(31,038)

(3,929)

24,555

7,297

(61,174)

97,079

508,679

677,143

14,433

1,200,255

(443,452)

(652,588)

(7,136)

(1,103,176)

65,227

24,555

7,297

97,079

CURRENT

Trade payables

Customer prepayments

Employee benefits – annual leave

Other payables

NOTE 15: PROVISIONS

CURRENT

Employee provisions

NON-CURRENT

Employee provisions

2018

728,958

188,503

294,175

257,765

2017

482,684

169,449

356,639

396,219

1,469,402

1,404,991

2018

2017

115,028

121,910

48,264

163,292

104,706

226,616

CARDIEX - ANNUAL REPORT 2018NOTE 16: FINANCIAL ASSETS

NON-CURRENT FINANCIAL ASSETS

Partial payment of convertible note

Total

2018

202,578

2017

In March 2018, the Company entered into a Convertible Note Purchase Agreement for the acquisition of a
convertible note (the “Note”) issued by Blumio, Inc, payable in two instalments.

As at 30 June 2018, US$150,000 of a total US$600,000 has been paid to the issuer, the balance of
US$450,000 is payable by November 2018, upon which date the Note will be issued. The Directors consider
that given the short-term nature of the financial asset, the fair value approximates the carrying value.

NOTE 17: BORROWINGS

CURRENT

Research and development tax incentive facility

Total

2018

185,000

2017

In the 2018 year, a facility was established under which the Company is entitled to withdraw funds to for
general liquidity management purposes. The facility is intended to be repaid by proceeds of the Company’s
2018 R&D tax incentive refund. The facility has a maximum limit of $320,000 and fixed interest rate of 1.25%
per month based on the drawn facility at the end of that month. The Company has signed a general security
agreement in favour of the lender. The termination date of the facility is the earlier of 31 December 2018 or 10
business days after the receipt of the Company’s R&D tax refund.

NOTE 18: ISSUED CAPITAL

No of Shares

2018

2017

(a) Ordinary shares

531,018,793

46,832,833

233,630,539

41,126,573

At the beginning of reporting period

233,630,539

41,126,573

201,720,539

39,126,899

Placements in the year

220,958,254

4,674,906

28,950,000

1,881,750

Shares issued subject to Restriction Agreement*

75,000,000

1,500,000

Shares issued in lieu of payment to suppliers

1,430,000

62,150

Shares issued on exercise of options

Cost of raising capital

2,960,000

242,800

(530,796)

(124,876)

Closing balance at reporting date

531,018,793

46,832,833

233,630,539

41,126,573

* On 31 May 2018, the Company issued 75 million shares subject to a Restriction Agreement. These shares are held on escrow and subject to a holding
lock until the full amount of consideration of $1.5 million is received, anticipated to be November 2018. See Note 26 for further information.

CARDIEX - ANNUAL REPORT 2018NOTE 18: ISSUED CAPITAL (CONT.)

All other ordinary shares are fully paid.

Ordinary shares participate in dividends and the proceeds on winding up of the Company in proportion to the
number of shares held. At the shareholders meetings each ordinary share is entitled to one vote when a poll is
called, otherwise each shareholder has one vote on a show of hands.

(b) Performance rights on issue

During 2018, 24,000,000 performance rights were issued under the following terms (further detail at Note 20):

Tranche

Number of performance rights

Will vest if 30 day VWAP exceeds:

8,000,000

$0.05

$0.08

$0.12

Throughout the period $4,466 was expensed and added to the share-based payments reserve in recognition
of these performance rights.

No of Options

2018

2017

150,050,958

45,430,602

17,233,333

2,243,864

At the beginning of reporting period

17,233,333

2,243,864

17,233,333

2,064,246

Options issued to broker in
November 2017 Placement

Options expired and transferred to
accumulated losses (Note 20)

Vesting of issued options to
employees

Free attaching options (1 for 2) as
part of Entitlements Issue

Free attaching options (1 for 2) as
attaching to placement

Free attaching options issued
subject to Restriction Agreement*

Options issued to broker in May
2018 placement

2,500,000

31,517

(4,680,000)

(1,278,642)

28,099,975

59,397,650

37,500,000

10,000,000

62,769

179,618

Closing balance at reporting date

150,050,958

1,059,508

17,233,333

2,243,864

* On 31 May 2018, the Company issued 75 million shares subject to a Restriction Agreement. These shares carried the right to a one for two free
attaching option on the same terms as the placement shares issued at the same time. Both the options and shares are held on escrow and subject to a
holding lock until the full amount of consideration of $1.5 million is received, anticipated to be November 2018.

CARDIEX - ANNUAL REPORT 2018NOTE 18: ISSUED CAPITAL (CONT.)

Fair Value of Options Granted

The weighted average assessed fair value at grant date of options granted during the year ended 2018 was
1.28 cents per option as no options were issued during the year (2017: $nil). The fair value at grant date is
determined using a Black Scholes option pricing model that takes into account the exercise price, the term of
the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying
share, the expected dividend yield and the risk free interest rate for the term of the option.

The model inputs for options granted and accrued during the year ended 30 June 2018 included:

(a) Number issued

(b) Exercise price

(d) Share price at grant date

(e) Share price volatility

(f) Expected dividend yield

(g) Risk-free interest rate

Options Granted
30 Nov 2017

Options Accrued at
30 Jun 2018

2,500,000

10,000,000

$0.038

4 years

$0.028

60%

2.16%

$0.050

3.5 years

$0.020

74%

2.3%

The expected price volatility is based on the historic volatility (based on the remaining life of the options),
adjusted for any expected changes to future volatility due to publicly available information.

Capital Management

Management controls the capital of the Group in order to maintain a good debt to equity ratio, provide the
shareholders with adequate returns and ensure that the Group can fund its operations and continue as a going
concern.

The Group’s capital includes ordinary share capital, shares and financial liabilities, supported by financial
assets. There are no externally imposed capital requirements.

Management effectively manages the Group’s capital by assessing the Group’s financial risks and adjusting
its capital structure in response to changes in these risks and in the market. These responses include the
management of debt levels, distribution to shareholders and share issues.

CARDIEX - ANNUAL REPORT 2018NOTE 19: RESERVES

Share-based payments reserve

Foreign currency translation reserve

Share-Based Payments Reserve

2018

1,063,974

507,524

1,571,498

2017

2,243,864

83,584

2,327,448

The based-payments reserve records the fair value of options and performance rights on issue.

Foreign Currency Reserve

The reserve is used to recognise exchange differences arising from the translation of the financial statements
of foreign operations to Australian dollars. It is also used to recognise gains and losses on hedges of the net
investments in foreign operations.

Share-based payments
reserve

Foreign currency
translation reserve

2,064,246

179,618

2,243,864

(288,406)

371,990

83,584

98,752

423,940

(1,278,642)

1,063,974

507,524

Total

1,775,840

551,608

2,327,448

522,692

(1,278,642)

1,571,498

Balance at 1 July 2016

Additions during the year

Balance at 30 June 2017

Additions during the year

Transfers to accumulated losses

Balance at 30 June 2018

NOTE 20: SHARE BASED PAYMENTS

a. Employee Share Option Plan (ESOP)

The CardieX (formerly AtCor Medical Holdings) Employee Option Plan was approved by shareholders at the
2005 Annual General Meeting and amendments were approved at the 2006 & 2008 Annual General Meetings.
All staff are eligible to participate in the plan at the discretion of the Directors (including Executive Directors)
following recommendations from the remuneration committee, a sub-committee of the CardieX Limited Board
of Directors.

Options are granted under the plan for no consideration. Options are granted for a 5-year period, and 33.3% Of
each new tranche vests and is exercisable after each of the first 3 anniversaries of the date of grant.

Options granted under the plan carry no dividend or voting rights.

When exercisable, each option is convertible into 1 ordinary share.

The exercise price of options is no less than the weighted average price at which the Company’s shares are
traded on the Australian Stock Exchange during the 5 trading days immediately before the options are granted.

CARDIEX - ANNUAL REPORT 2018NOTE 20: SHARE BASED PAYMENTS (CONT.)

a. Employee Share Option Plan (ESOP) (Cont.)

Set out below are summaries of options granted under the plan:

2018:

Grant Date

Expiry date

Exercise
price

Balance at
start of the
year

Granted
during the
year

Exercised
during the
year

Expired/
Forfeited
during the
year

Balance at
end of the
year

Exercisable
at end of
the year

Number

23-Aug-12

23-Aug-17

$0.075

2,455,000

5-Oct-12

5-Oct-17

$0.075

200,000

26-Oct-12

26-Oct-17

$0.084

1,400,000

19-Nov-12

19-Nov-17

$0.085

125,000

29-Aug-13

29-Aug-18

$0.139

2,998,333

31-Oct-13

31-Oct-18

$0.181

2,100,000

28-Aug-14

28-Aug-19

$0.112

1,825,000

24-Mar-15

24-Mar-20

$0.194

350,000

20-Aug-15

20-Aug-20

$0.256

2,430,000

13-Nov-15

13-Nov-19

$0.261

2,000,000

13-Nov-15

13-Nov-20

$0.250

1,000,000

12-Feb-16

12-Feb-21

$0.199

350,000

Total

Weighted average exercise price

17,233,333

$0.17

(2,455,000)

(200,000)

(1,400,000)

(125,000)

2,998,333

2,100,000

1,825,000

(350,000)

2,430,000

1,620,000

2,000,000

1,000,000

(150,000)

200,000

666,667

133,333

(4,680,000)

12,553,333

11,343,333

$0.09

$0.19

500,000 Options were forfeited during 2018 due to terminating employment, (2017: 965,000) and 4,180,000
options expired (2017: 1,297,500) in the same period. No options were exercised during 2018 (2017:
1,500,000).

CARDIEX - ANNUAL REPORT 2018NOTE 20: SHARE BASED PAYMENTS (CONT.)

a. Employee Share Option Plan (ESOP) (Cont.)

2017:

Grant Date

Expiry date Exercise
price

Balance at
start of the
year

Granted
during the
year

Exercised
during the
year

Expired/
Forfeited
during the year

Balance at
end of the
year

Exercisable
at end of the
year

Number

21-Oct-11

21-Oct-16

$0.084

1,500,000

16-Feb-12

16-Feb-17

$0.098

1,297,500

23-Aug-12

23-Aug-17

$0.075

2,555,000

5-Oct-12

5-Oct-17

$0.075

200,000

26-Oct-12

26-Oct-17

$0.084

1,400,000

19-Nov-12

19-Nov-17

$0.085

125,000

29-Aug-13

29-Aug-18

$0.139

3,193,333

31-Oct-13

31-Oct-18

$0.181

2,100,000

28-Aug-14

28-Aug-19

$0.112

1,825,000

24-Mar-15

24-Mar-20

$0.194

350,000

20-Aug-15

20-Aug-20

$0.256

2,600,000

13-Nov-15

13-Nov-19

$0.261

2,000,000

13-Nov-15

13-Nov-20

$0.250

1,000,000

18-Jan-16

18-Jan-21

$0.197

500,000

12-Feb-16

12-Feb-21

$0.199

350,000

Total

20,995,833

Weighted average exercise price

$0.16

b. Performance rights

(1,500,000)

(1,297,500)

(100,000)

2,455,000

200,000

1,400,000

125,000

(195,000)

2,998,333

2,100,000

1,825,000

1,216,667

350,000

233,333

(170,000)

2,430,000

1,620,000

2,000,000

1,000,000

333,334

(500,000)

350,000

116,667

(1,500,000)

(2,262,500)

17,233,333

14,798,334

$0.08

$0.13

$0.17

$0.16

The CardieX Option and Performance Rights Plan was approved by shareholders at the Extraordinary General
Meeting held on 28 May 2018.

During 2018, 24,000,000 performance rights were issued under the following terms:

Tranche

Number of performance rights

Will vest if 30 day VWAP exceeds:

8,000,000

$0.05

$0.08

$0.12

a. The performance rights will be issued for no consideration and if they vest and are exercised, the resulting
shares will be fully paid ordinary shares in the capital of the Company issued on the same terms and
conditions as the Company’s existing ordinary shares.

b. No individual has previously received securities under this plan as this is the first time the Company has

proposed an issue of securities under the plan; and

c. No loans or other financial assistance have or will be made by the Company in connection with the issue of

the relevant performance rights.

CARDIEX - ANNUAL REPORT 2018NOTE 20: SHARE BASED PAYMENTS (CONT.)

c. Expenses arising from share based payment transactions

Total expenses arising from share based payment transactions recognised during the period as part of
employee benefit expense were as follows:

2018

4,466

2017

179,618

2018

(42,125,535)

(2,961,225)

1,278,642

2017

(37,761,964)

(4,363,571)

(43,808,118)

(42,125,535)

(2,961,225)

(4,363,571)

61,174

58,572

26,482

133,308

491,910

108,664

(85,301)

128,096

(2,038,320)

84,990

179,618

387,844

526,757

(45,426)

(4,687)

168,845

(3,065,630)

Options issued to broker

Rights issued under Option and Performance Rights Plan

NOTE 21: ACCUMULATED LOSSES

Opening balance at 1 July

Losses for the year

Transfer from share based payments reserve

Closing balance at 30 June

NOTE 22: CASH FLOW INFORMATION

Reconciliation of Cash Flow from Operations with Loss after Income Tax

Loss after income tax

Non-cash flows in profit:

Depreciation and amortisation

Inventory impairment expense

Share based payments expense

Bad debts expense

Unrealised foreign exchange difference

Changes in current assets and liabilities:

Decrease in trade and other receivables

Increase in inventories

(Increase) in other operating assets

Increase in trade and other payables and provisions

Net cash used in operating activities

CARDIEX - ANNUAL REPORT 2018NOTE 23: EVENTS AFTER THE BALANCE SHEET DATE

No significant subsequent event has arisen that significantly affects the operations of the Group.

NOTE 24: CAPITAL AND FINANCIAL RISK MANAGEMENT

Capital management

The Group’s objectives when managing the Company’s share capital, reserves and accumulated losses, which
represents the Group’s capital, are to:

• Safeguard their ability to continue as a going concern, so that they can continue to provide returns for

shareholders and benefits for other stakeholders; and

• Sustain future product development.

Financial risk management

The Group’s activities expose it to a variety of financial risks: market risk (primarily currency risk), credit risk,
and liquidity risk. The Group’s overall risk management program focuses on the unpredictability of financial
markets and seeks to minimise potential adverse effects on the financial performance of the Group. The Group
uses different methods to measure different types of risk to which it is exposed. These methods include
sensitivity analysis in the case of foreign exchange risk and aging analysis for credit risk.

Financial risk management is carried out by the Chief Financial Officer (CFO) and overseen by the Audit & Risk
Committee, a subcommittee of the Board of Directors.

a. Market risk

Foreign exchange risk

Foreign exchange risk arises when future commercial transactions and recognised assets and liabilities are
denominated in a currency that is not the entity’s functional currency. The risk is measured using sensitivity
analysis and cash flow forecasting.

The Group operates internationally and is exposed to foreign exchange risk arising from currency exposures to
the US dollar and the Euro.

The Group’s exposure to foreign currency exchange risk at the reporting date was as follows:

30 June 2018

30 June 2017

In USD

1,062,768

83,952

(437,188)

In EUR

226,063

40,865

(14,136)

In USD

107,156

50,672

(112,236)

In EUR

165,802

92,158

(18,938)

Trade Receivables

Financial Assets

Trade Payables

CARDIEX - ANNUAL REPORT 2018NOTE 24: CAPITAL AND FINANCIAL RISK MANAGEMENT (CONT.)

Sensitivity

Based on the financial instruments held at 30 June 2018, had the Australian dollar weakened/strengthened by
10% against the US dollar with all other variables held constant, the Group’s pre-tax result for the year would
have varied by $47,762/($58,375) (2017: $6,600/($5,939)). Had the Australian dollar weakened/strengthened
by 10% against the Euro with all other variables held constant, the Group’s pre-tax result for the year would
have varied by $36,283/($44,346) (2017: $39,483/($35,536)).

b. Credit risk

Credit risk arises from cash and cash equivalents, derivative financial instruments and deposits with banks
and financial institutions, as well as credit exposures to customers, including outstanding receivables and
committed transactions. The Group has no significant concentrations of credit risk. For banks and financial
institutions, only independently rated and reputable parties are accepted. The Group has policies in place to
ensure that sales of products and services are made to customers with an appropriate credit history. Terms of
trade provided to creditworthy customers are between 30 and 90 days, whilst customers deemed higher risk
arrange a letter of credit or prepay for goods. The maximum exposure to credit risk at the reporting date is the
carrying amount of the financial assets.

c. Liquidity risk

Prudent liquidity risk management implies maintaining sufficient cash and marketable securities, the
availability of funding through an adequate amount of committed credit facilities and the ability to close out
market positions. The Group manages liquidity risk by continuously monitoring forecast and actual cash flows
and matching the maturity profiles of financial assets and liabilities.

d. Fair value estimation

The fair value of financial assets and financial liabilities must be estimated for recognition and measurement
or for disclosure purposes. The carrying value less impairment provision of trade receivables and payables are
assumed to approximate their fair values due to their short-term nature. The fair value of financial liabilities
approximates their carrying values.

NOTE 25: SEGMENT REPORTING

a. Description of segments

In the 2018 financial year, the Group operated in one operating segment, being sales of cardiovascular devices
and services to hospitals, clinics, research institutions and pharmaceutical companies.

Management has determined the reporting segments based on the reports reviewed by the Board of Directors
that are used to make strategic decisions. The Board generally considers the business from a geographical
perspective and has identified three reportable segment by geographic area.

Geographic areas are:

• Americas (includes global pharmaceutical trials business)

• Europe (includes Middle East and Africa)

• Asia Pacific (includes Asia & Australia/NZ)

CARDIEX - ANNUAL REPORT 2018NOTE 25: SEGMENT REPORTING (CONT.)

b. Segmental information provided to the Board

2018

Americas

Europe

Asia Pacific

Sales to external customers

2,813,689

708,717

483,685

Consolidated

Inter
segment
eliminations/
unallocated

4,006,091

Intersegment sales

Total sales revenue

Other revenue/income

1,525,347

(1,525,347)

2,813,689

708,717

2,009,032

(1,525,347)

4,006,091

434,831

Total segment revenue/income

2,813,689

708,717

2,443,863

(1,525,347)

4,420,922

Segment result

(1,467,704)

(69,131)

(1,022,850)

(406,098)

(2,965,783)

Unallocated revenue less unallocated expenses

Loss before income tax

Income tax expense

Loss for the year

Segment assets

Segment liabilities

2017

4,558

(2,961,225)

18,492,094

33,016,707

58,751,024

(70,829,211)

6,413,907

55,911,613

(87,110,626)

1,817,694

Americas

Europe

Asia Pacific

Consolidated

Inter
segment
eliminations/
unallocated

4,327,283

Sales to external customers

2,849,885

721,549

755,849

Intersegment sales

Total sales revenue

Other revenue/income

1,498,766

(1,498,766)

2,849,885

721,549

2,254,615

(1,498,766)

4,327,283

470,248

Total segment revenue/income

2,849,885

721,549

2,724,863

(1,498,766)

4,797,531

Segment result

(1,197,713)

53,583

(2,826,155)

(3,970,285)

(393,286)

(4,363,571)

17,791,103

29,593,588

45,383,977

(60,259,408)

2,915,672

48,494,247

(76,500,649)

1,587,186

Unallocated revenue less unallocated expenses

Loss before income tax

Income tax expense

Loss for the year

Segment assets

Segment liabilities

CARDIEX - ANNUAL REPORT 2018
NOTE 25: SEGMENT REPORTING (CONT.)

c. Notes to and forming part of the segment information

Intersegment Transfers

Segment revenues, expenses and results include transfers between segments. The Group transfer inventory
and finished goods between its group companies. Such transfers are priced on an ‘’arm’s-length’’ basis and are
eliminated on consolidation.

Segment Revenue

There was no significant concentration of revenue attributable to one customer in 2018 (2017: $nil).

NOTE 26: RELATED PARTY TRANSACTIONS

Subsidiaries

The Group’s principal subsidiaries at 30 June 2018 are set out below. Unless otherwise stated, they have share
capital consisting solely of ordinary shares that are held directly by the Group, and the proportion of ownership
interests held equals the voting rights held by the Group. The country of incorporation or registration is also
their principal place of business.

Name of Entity

Country of Incorporation

Percentage Owned

AtCor Medical Pty Ltd

AtCor Medical, Inc. (Delaware C Corp)

Australia

USA

2018

100%

2017

100%

CARDIEX - ANNUAL REPORT 2018NOTE 26: RELATED PARTY TRANSACTIONS (CONT.)

Key Management Personnel Compensation

Salary and Directors
Fees

Performance Rights
Issued

Post-Employment
Benefits

2018

Mr. Donal O’Dwyer

Mr. Niall Cairns

Mr. King Nelson

Mr. Craig Cooper

Dr. David Brookes

Mr. Duncan Ross

Dr. Michael O’Rourke

Total Compensation

2017

Mr. Donal O’Dwyer

Mr. King Nelson

Dr. David Brookes

Mr. Duncan Ross

Dr. Michael O’Rourke

Total Compensation

50,228

28,000

27,955

225,863

18,949

179,830

9,513

540,338

68,750

37,182

37,500

429,619

31,250

604,301

4,466

4,772

3,551

13,439

904

22,666

16,597

11,490

69,688

11,490

120,755

Shares held by key management personnel and their associates

Total

55,000

28,000

27,955

230,329

22,500

193,269

10,417

567,470

85,347

48,672

48,990

499,307

42,740

725,056

Balance
01 July 20171

6,067,517

3,000,0001

153,846

-1

1,469,264

4,603,052

10,641,396

25,935,075

Share split

Additions

6,111,110

75,000,0002

555,555

925,925

157,592,590

Balance
30 June 2018

12,178,627

78,000,000

153,846

75,000,000

2,024,8193

4,603,0523

11,567,3213

183,527,665

Shares held at date of appointment.

Mr. Donal O’Dwyer

Mr. Niall Cairns

Mr. King Nelson

Mr. Craig Cooper

Dr. David Brookes

Mr. Duncan Ross

Dr. Michael O’Rourke

Total

3. Held at date of resignation.

CARDIEX - ANNUAL REPORT 2018NOTE 26: RELATED PARTY TRANSACTIONS (CONT.)

Options Held by Key Management Personnel and Their Associates

Donal O’Dwyer

Niall Cairns

King Nelson

Craig Cooper

David Brookes

Duncan Ross

Michael O’Rourke

Total

Balance
01 July 20171

650,000

-1

450,000

-1

450,000

3,100,000

450,000

5,100,000

Share split

Additions

2,500,000

37,500,0002

77,500,000

Balance
30 June 2018

3,150,000

37,500,000

450,000

37,500,000

450,0003

3,100,0003

450,0003

82,600,000

1. Options held at date of appointment.

3. Held at date of resignation.

4. Options acquired by key management personnel and their associates in the year related are free attaching options on shares purchased.

Performance Rights Held Key Management Personnel and Their Associates

Mr Craig Cooper holds 24 million performance rights which vest subject to a set of milestones as follows:

Number of performance rights Will vest if 30 Day VWAP exceeds:

Expiry Date of Performance
Milestone

Tranche 1

Tranche 2

Tranche 3

Employment agreements

8 million

$0.05

$0.08

$0.12

28/05/2021

Craig Cooper – Chief Executive Officer

• Agreement commenced on 1 December 2017.

• Base salary of US$300,000 per annum.

• Reimbursement for reasonable administrative expenses incurred in running the USA business, paid on a

monthly basis up to US$5,000 per month.

CARDIEX - ANNUAL REPORT 2018NOTE 26: RELATED PARTY TRANSACTIONS (CONT.)

Niall Cairns – Non-Executive Director

• Agreement commenced with an effective date of 1 March 2018.

• Monthly consulting fee for strategic review and consulting services of AU$7,000 per month.

• Reimbursement for reasonable administrative expenses incurred.

Loans to Directors and Key Management Personnel

During the year the Company entered into a Deed of Undertaking with C2 Ventures Pty Limited, a related party
of Mr Niall Cairns and Mr Craig Cooper. Under the Deed of Undertaking C2 Ventures Pty Limited subscribed
for 75,000,000 shares and 37,500,000 free attaching options on a one for two basis on the same terms as
offered to shareholders under the entitlements issue. Under the Deed of Undertaking C2 Ventures Pty Limited
is required to pay the total subscription monies ($1,500,000) in full before 30 November 2018.

The arrangement was approved by shareholders at the Extraordinary General Meeting held on 28 May 2018.

NOTE 27: PARENT ENTITY DISCLOSURES

Financial position

Assets

Total current assets

Total assets

Liabilities

Total current liabilities

Total liabilities

Equity

Contributed equity

Reserves

Accumulated losses

Total equity

Financial performance

Loss for the year

Other comprehensive income

Total comprehensive loss

2018

2017

1,508,603

23,834,293

1,270,305

17,672,116

53,387,892

1,001,205

237,051

16,763,571

771,380

15,800,785

47,583,863

2,243,864

(48,226,920)

(48,864,942)

6,162,177

962,785

(638,021)

(32,742,938)

(638,021)

(32,742,938)

CARDIEX - ANNUAL REPORT 2018NOTE 27: PARENT ENTITY DISCLOSURES (CONT.)

a. Explanation of loss in 2017 financial year

In the 2017 financial year, the investment in subsidiaries of $15,132,000 was written down to nil due to the
results of the Group. Additionally, an impairment of $17,000,000 was recognised against the intercompany
receivables in the parent entity.

No further impairment was recognised in the 2018 financial year.

b. Guarantees entered into by the parent entity

No guarantees have been entered into by the parent entity during 2018 or 2017.

c. Contingent liabilities of the parent entity

The parent entity did not have any contingent liabilities as at 30 June 2018 or 30 June 2017

NOTE 28: CAPITAL COMMITMENTS

At 30 June 2018, the parent entity had a contractual commitment to pay US$450,000 under the Convertible
Note Purchase Agreement with Blumio, Inc.

The Company has committed to pay US$450,000 in November 2018 as the second and final payment for its
total US$600,000 investment in Blumio, Inc.

There are no other capital commitments present for the Group at balance date.

NOTE 29: COMPANY DETAILS

The Registered Office of the Company is:

CardieX Limited

Suite 11

1059-1063 Victoria road

West Ryde NSW 2114

The Principal Place of Business is:

CardieX Limited

Suite 11

1059-1063 Victoria road

West Ryde NSW 2114

CARDIEX - ANNUAL REPORT 2018DIRECTORS’ DECLARATION

The Directors of the Company Declare that:

1. The financial statements and notes, as set out on pages 27 to 58, are in accordance with the

Corporations Act 2001 and:

a. Comply with Accounting Standards and the Corporations Regulations 2001; and

b. Give a true and fair view of the financial position as at 30 June 2018 and of the performance for the

year ended on that date of the Company and Consolidated Group.

2. The Company has included in Note 1 to the financial statements an explicit and unreserved statement of

compliance with International Financial Reporting Standards;

3. The Directors have been given the declaration required by section 295a of the Corporations Act from the

Chief Executive Officer for the financial year ended 30 June 2018;

In the Director’s opinion there are reasonable grounds to believe that the Company will be able to pay its
debts as and when they become due and payable; and

5. The remuneration disclosures included on pages 21 to 25 of the Directors’ Report (as part of the Audited
Remuneration Report) for the year ended 30 June 2018, comply with section 300A of the Corporations
Act 2001.

6. This declaration is made in accordance with a resolution of the Board of Directors.

Donal O’Dwyer
Chairman
Sydney, 31 August 2018

CARDIEX - ANNUAL REPORT 2018I N D E P E N D E N T A U D I T O R ’ S R E P O R T

INDEPENDENT AUDITOR’S REPORT

Tel: +61 2 9251 4100
Fax: +61 2 9240 9821
www.bdo.com.au

Level 11, 1 Margaret St
Sydney NSW 2000
Australia

INDEPENDENT AUDITOR'S REPORT

To the members of CardieX Limited

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of CardieX Limited (the Company) and its subsidiaries (the
Group), which comprises the consolidated statement of financial position as at 30 June 2018, the
consolidated statement of profit or loss and other comprehensive income, the consolidated statement
of changes in equity and the consolidated statement of cash flows for the year then ended, and notes
to the financial report, including a summary of significant accounting policies and the directors’
declaration.

In our opinion the accompanying financial report of the Group, is in accordance with the Corporations
Act 2001, including:

(i)

Giving a true and fair view of the Group’s financial position as at 30 June 2018 and of its
financial performance for the year ended on that date; and

(ii)

Complying with Australian Accounting Standards and the Corporations Regulations 2001.

Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under
those standards are further described in the Auditor’s responsibilities for the audit of the Financial
Report section of our report. We are independent of the Group in accordance with the Corporations
Act 2001 and the ethical requirements of the Accounting Professional and Ethical Standards Board’s
APES 110 Code of Ethics for Professional Accountants (the Code) that are relevant to our audit of the
financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance
with the Code.

We confirm that the independence declaration required by the Corporations Act 2001, which has been
given to the directors of the Company, would be in the same terms if given to the directors as at the
time of this auditor’s report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis
for our opinion.

CARDIEX - ANNUAL REPORT 2018
I N D E P E N D E N T A U D I T O R ’ S R E P O R T

Material uncertainty related to going concern

We draw attention to Note 1 in the financial report which describes the events and/or conditions which
give rise to the existence of a material uncertainty that may cast significant doubt about the group’s
ability to continue as a going concern and therefore the group may be unable to realise its assets and
discharge its liabilities in the normal course of business. Our opinion is not modified in respect of this
matter.

Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in
our audit of the financial report of the current period. We have determined that there are no key
audit matters to communicate in our report in addition to the matter described in the Material
uncertainty related to going concern section.

Other information

The directors are responsible for the other information. The other information comprises the
information in the Group’s annual report for the year ended 30 June 2018, but does not include the
financial report and the auditor’s report thereon.

Our opinion on the financial report does not cover the other information and we do not express any
form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information
and, in doing so, consider whether the other information is materially inconsistent with the financial
report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this
other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the directors for the Financial Report

The directors of the Company are responsible for the preparation of the financial report that gives a
true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001
and for such internal control as the directors determine is necessary to enable the preparation of the
financial report that gives a true and fair view and is free from material misstatement, whether due to
fraud or error.

In preparing the financial report, the directors are responsible for assessing the ability of the group to
continue as a going concern, disclosing, as applicable, matters related to going concern and using the
going concern basis of accounting unless the directors either intend to liquidate the Group or to cease
operations, or has no realistic alternative but to do so.

Auditor’s responsibilities for the audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free
from material misstatement, whether due to fraud or error, and to issue an auditor’s report that
includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an
audit conducted in accordance with the Australian Auditing Standards will always detect a material
misstatement when it exists. Misstatements can arise from fraud or error and are considered material
if, individually or in the aggregate, they could reasonably be expected to influence the economic
decisions of users taken on the basis of this financial report.

CARDIEX - ANNUAL REPORT 2018

I N D E P E N D E N T A U D I T O R ’ S R E P O R T

A further description of our responsibilities for the audit of the financial report is located at the
Auditing and Assurance Standards Board website at:

http://www.auasb.gov.au/auditors_responsibilities/ar1.pdf

This description forms part of our auditor’s report.

Report on the Remuneration Report

Opinion on the Remuneration Report

We have audited the Remuneration Report included in pages 15 to 18 of the directors’ report for the
year ended 30 June 2018.

In our opinion, the Remuneration Report of CardieX Limited, for the year ended 30 June 2018, complies
with section 300A of the Corporations Act 2001.

Responsibilities

The directors of the Company are responsible for the preparation and presentation of the
Remuneration Report in accordance with section 300A of the Corporations Act 2001. Our responsibility
is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with
Australian Auditing Standards.

BDO East Coast Partnership

Grant Saxon
Partner

Sydney, 31 August 2018

CARDIEX - ANNUAL REPORT 2018

A D D I T I O N A L I N F O R M A T I O N F O R P U B L I C L I S T E D C O M P A N I E S

Additional information required by the ASX listing rules and not disclosed elsewhere in this report is set out
below.

Distribution Schedule of Equity Securities

Spread of Holdings

100,001 and Over

10,001 to 100,000

5,001 to 10,000

1,001 to 5,000

1 to 1,000

Total

Unmarketable Parcels

No. of Holders

472

716

148

113

501,053,944

30,172,549

1,181,456

403,340

7,505

1,507

532,818,794

There were 397 shareholders holding less than a marketable parcel totalling 2,554,378 shares as at 29
August 2018.

Top 20 Holdings as at 29 August 2018

Holder Name

C2 VENTURES PTY LIMITED

MR PAUL COZZI

SAFARI CAPITAL PTY LTD

CB CO PTY LTD

MRS JANE GREENSLADE

MR PAUL JOSEPH COZZI

HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED

DRUMNADROCHIT FUTURES PTY LTD

CPO SUPERANNUATION FUND PTY LTD

CITICORP NOMINEES PTY LIMITED

AUSTRALIAN EXECUTOR TRUSTEES LIMITED

DUNDRUM INVESTMENTS PTY LTD

PEHILA PTY LTD

PROF MICHAEL FRANCIS O’ROURKE

CALAMA HOLDINGS PTY LTD

MR DONALD O’DWYER & MRS JUDITH O’DWYER

BNP PARIBAS NOMINEES PTY LTD

MR PAWEL REJ & MRS MIROSLAWA REJ

PUNTERO PTY LTD

SYMINGTON PTY LTD

TOTAL

Balance at
29 Aug 2018

75,000,000

22,287,782

16,300,337

15,470,000

10,996,504

10,640,284

9,118,421

9,068,574

8,830,000

7,928,325

7,274,389

6,983,725

5,896,951

5,670,370

5,625,353

5,194,902

4,912,225

4,490,901

4,074,262

3,894,649

14.08

4.18

3.06

2.90

2.06

2.00

1.71

1.70

1.66

1.49

1.37

1.31

1.11

1.06

0.97

0.92

0.84

0.76

0.73

239,657,954

44.98

CARDIEX - ANNUAL REPORT 2018A D D I T I O N A L I N F O R M A T I O N F O R P U B L I C L I S T E D C O M P A N I E S

Substantial Shareholders

The names of substantial shareholders who have notified the Company in accordance with section 671B of
the Corporations Act 2001 are:

Holder Name

C2 Ventures Pty Limited

Paul Cozzi

Number of Ordinary Fully Paid Shares
Held

% Held of Issued Ordinary Capital

75,000,000

32,928,066

14.08

6.20

Statement Regarding Use of Cash and Assets

CardieX Limited utilised cash and assets in a form readily convertible to cash that it had at the time of
admission consistent with the business objectives and use of funds stated in the prospectus lodged with the
ASX and dated 23 April 2018.

The Name of the Company Secretary is:

Jarrod Travers White

Registered Office and Principal Place of Business

1059-1063 Victoria Rd

West Ryde NSW 2114

Telephone: (02) 9874 8761

Email: info@cardiex.com

Website: www.CardieX.com

CARDIEX - ANNUAL REPORT 2018